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Atherothrombosis is the causal event in acute myocardial infarction and stroke. These 
occlusive arterial thrombi require the confluence of high shear rates from a stenosis, 
exposure of mural collagen from a ruptured plaque cap, and the aggregation of platelets on 
elongated vWF. A functional assay of thrombotic occlusion would be able to diagnose the 
propensity of individual patients to occlude and determine patient-specific drug regimens. 
Current platelet function tests do not have the relevant fluid mechanics, collagen surface, 
or proper anticoagulant to mimic arterial thrombotic occlusion. I have created an improved 
microfluidic assay that includes all the above factors, uses a small amount of whole blood, 
and is validated against clinical thrombosis over two orders of magnitude in size.   
Antiplatelet therapies, such as aspirin and clopidogrel, have been developed to 
irreversibly inhibit platelet activation or binding. However, they do not work as intended 
for a large percentage of the population, as up to 60% of patients exhibit resistance to 
therapy per current non-specific platelet assays. Resistance persists even with dual 
antiplatelet therapy (DAPT). The poor therapeutic efficacy of current anti-platelet agents 
with their associated major bleeding risks indicate the need for both a functional thrombosis 
assay and improved antithrombotic agents. 
The overall goal of this thesis is to develop a low variability device for clinical 
diagnostics and arterial thrombosis research. I hypothesize that the main sources of 
variability observed in previous microfluidic assays of thrombosis are due to three 
fundamental design factors of high relevance to arterial thrombosis. Secondly, I 
 xxi 
hypothesize that the endpoint of occlusion time in the improved assay will be sensitive to 
antiplatelet responsiveness. Finally, I hypothesize that such a device can be utilized to 
develop and evaluate new antithrombotic nanoparticle therapies. Both in vitro and in vivo 
models of thrombosis will be utilized to investigate the hypotheses in this thesis. 
 
 1 
CHAPTER 1. INTRODUCTION 
 
1.1 Myocardial Infarction and Ischemic Stroke 
Arterial thrombosis is the condition where a platelet aggregate forms at the site of an 
atherosclerotic injury and occludes blood flow to major organs such as the heart and brain, 
leading to a heart attack or ischemic stroke. Heart attacks, also known as myocardial 
infarctions, and ischemic strokes are major adverse cardiovascular events (MACE) that are 
the leading causes of death in the United States. Myocardial infarction, where a blood clot 
develops in the coronary arteries and restricts blood flow to heart muscle, is the largest 
contributor to this percentage. It is estimated that approximately 720,000 Americans will 
have a first-time myocardial infarction this year, with approximately 335,000 having a 
recurring event [1]. Ischemic stroke occurs when a thrombotic embolus becomes lodged in 
the cerebrovasculature and prevents blood flow. There are approximately 610,000 new 
cases of ischemic stroke each year in the United States, with approximately 185,000 
recurrent events [1]. While these cardiovascular complications accounted for 23.6% of all 
deaths in 2018, they also can impose life-long complications on survivors, such as 
paralysis, weakness, and the need for daily medications [1]. 
The annual financial burden resulting from these conditions is enormous, with the 
combination of direct and indirect costs for heart disease and stroke related conditions 
being $244.9B in 2014 [1]. This number is projected to grow to a staggering $500B by 
2035. The costs associated with cardiovascular diseases significantly outpace the costs of 
all other pathological and disease categories. 
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To reduce these costs (or at least the rate of growth) continued research into improved 
diagnostics and therapies is needed. The current initial therapy of choice for patients at risk 
of myocardial infarction or stroke is daily low-dose aspirin to prevent the formation of 
platelet aggregates, or thrombi. This may be combined with another therapy as a dual 
antiplatelet therapy (DAPT) approach, but the cardiologist must weigh in factors such as 
the patient’s relative risk for MACE and their risk for a bleeding event, which is enhanced 
through the usage of antithrombotic or antiplatelet therapies. Typically, this choice is made 
through the cardiologist’s judgment of risk factor (i.e. medical history and age) rather than 
through quantifiable means with a diagnostic test. If a patient experiences either myocardial 
infarction or stroke while on therapy, a new therapeutic plan must be initiated to overcome 
this “antiplatelet resistance” and prevent a subsequent event. 
Therefore, the remaining sections of this thesis chapter will go into more detail about 
the pathology of arterial thrombosis, as well as current therapies to prevent the formation 
of arterial thrombi and diagnostics to determine the efficacies of those therapies. The aims 
of this thesis to progress the field of thrombotic therapies and diagnostics will then be 
specified. 
1.2 The Role of Platelets and von Willebrand Factor 
The critical common factor in myocardial infarction and ischemic stroke is 
thrombosis occurring in an atherosclerotic artery. Initiated by plaque-cap rupture of an 
atherosclerotic artery due to pathophysiological high shear blood flow, a platelet-rich, 
white clot forms. This phenomenon diverges from the classical Virchow’s Triad for 
coagulation, as arterial thrombosis requires: 1) high shear blood flow, 2) a pro-thrombotic 
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surface, and 3) platelets and von Willebrand Factor (vWF) [2, 3]. While the development 
of atherosclerosis is responsible for the narrowing of the artery to create high shear and 
eventually disrupting the endothelial cell layer, the blood components platelets and vWF 
are always in the flow. 
Platelets are anuclear cell fragments in the blood circulation that make up just 1% of 
the blood volume. Originating from bone marrow, they are known for playing a major role 
in blood clot formation and wound healing [4]. Platelets will adhere to the site of vascular 
injury and begin to form what is commonly termed as the “platelet plug” to block off the 
injury site from circulation. This is mediated by platelet membrane glycoproteins GPIb and 
GPIIb/IIIa. GPIb allows for the initial adhesion of platelets to clotting proteins at the injury 
site, while GPIIb/IIIa allows for clot strengthening interactions [5-7]. In addition, platelets 
have internal stores of many important molecules and proteins in α- and dense-granules. 
These include clotting factors such as ADP and calcium that are significant players in 
generating platelet activation, as well as clotting proteins fibrinogen and von Willebrand 
Factor [8]. 
vWF is a multimeric protein secreted by both Weibel-Palade bodies (WPB) in 
endothelial cells and α-granules in megakaryocytes [9]. Each monomer of vWF consists of 
a series of 29 subdomains that function in protein-protein and protein-cell interactions. The 
250 kDa monomer will dimerize head-to-head, and the dimers continue to polymerize to 
create very long vWF chains that may reach sizes of 20,000 kDa [10]. Endothelial cell 
vWF is released into circulation and remains in plasma, while megakaryocyte vWF is 
stored in α-granules of platelets as previously mentioned. Both play a role in the formation 
of arterial thrombi [11]. Under physiological flow, plasma vWF typically circulates in a 
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globular confirmation due to self-association of the vWF dimers, thereby shielding many 
of its binding domains. However, in the pathological scenario described below vWF 
unfolding can initiate the thrombotic process that leads to myocardial infarction and 
ischemic stroke. 
First, a pro-thrombotic surface is established by high shear blood flow disrupting the 
endothelial cell layer of the artery. Sub-endothelial collagen is then exposed to blood, 
creating a pro-thrombotic surface. vWF has a mechanosensitive tertiary structure and 
begins to unravel in the high shear (> 5000 s-1) flow environment as the self-associations 
of vWF dimers are overcome by the shearing force of the blood flow. This exposes many 
of the binding domains of the vWF protein, specifically the C3 domain that binds and 
tethers to the exposed collagen in this case. A layer of vWF proteins begins to accumulate 
at the wall, creating an even more pro-thrombotic surface for platelets. The A1 domain of 
vWF, now exposed and at a high concentration on the surface, binds specifically to platelet 
GPIb. This is able to happen because platelets are pushed toward the vessel walls by red 
blood cells in flow, and therefore have a higher concentration near the surface [12]. The 
A1-GPIb bond acts as an extraordinarily fast catch-bond that grabs platelets from the flow. 
While the GPIb bond is highly reversible, there are several thousand A1-GPIb bonds that 
keep the platelet tethered [11, 13]. Due to the increased residence time in the high shear 
zone, platelets become activated [14]. Platelet activation triggers significantly stronger 
GPIIb/IIIa bonds with vWF, which form to nearly irreversibly tether the platelet. Activated 
platelets then release α-granules, which secret significantly higher concentrations of vWF 
to the thrombotic site. Rapid platelet accumulation is then propagated in the area until 
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occlusive thrombus forms in the vessel, restricting blood flow and leading to complications 
of myocardial infarction or ischemic stroke [2].  
1.3 Current Antithrombotic Therapies 
Several drugs exist for the prevention of platelet thrombosis. Each of these therapies 
targets platelet activation specifically, which would thereby prevent the strong binding of 
GPIIb/IIIa and the additional release of α-granule vWF from platelets. This section will 
discuss the targets of common antiplatelet therapies, as well as their performance in the 
clinic. 
1.3.1 Aspirin (Acetylsalicylic Acid) 
Aspirin was first utilized as an antithrombotic agent in the 1950’s by Dr. Lawrence 
Craven, and has become a mainstay in preventative therapy ever since [15]. Craven 
developed his hypothesis after noticing that his patients who chewed aspirin gum exhibited 
more bleeding complications during surgery. This led to further investigation into the 
mechanism by which aspirin may be impacting hemostatic function. It was found that 
aspirin acts by targeting cyclooxygenase (COX-1) dependent platelet activation [16]. The 
inhibition of COX-1 prevents the necessary synthesis of prostaglandin G2 (PGG2), 
prostaglandin H2 (PGH2), and thromboxane A2 (TXA2) for the activation of platelets. 
Craven developed his own clinical trial for the rates of myocardial infarction in a cohort 
of 8,000 patients. This study showed that no patients that faithfully stuck to their aspirin 
dosage experienced a heart attack, which was very striking to the community at the time 
[17]. However, there is serious speculation that this study (and others that followed) were 
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not adequately controlled in the wake of recent clinical results. Three large clinical studies 
reported at the end of 2018 indicate that the effects of aspirin are negligible in primary 
prevention of MACE. These three studies are the ARRIVE (Aspirin to Reduce Risk of 
Initial Vascular Events), ASCEND (A Study of Cardiovascular Events iN Diabetes), and 
ASPREE (Aspirin in Reducing Events in the Elderly) trials. Both the ARRIVE and 
ASPREE trials indicated no significant difference in the occurrence of MACE between 
individuals taking aspirin or placebo treatment [18-21]. The same trials also showed a 
significant increase (hazard ratio 1.38) in the incidence of major hemorrhagic bleeding 
associated with aspirin use. The ASCEND trial did find a significant difference in the 
occurrence of MACE between aspirin and placebo groups for diabetic patients, but this 
was also countered by a significant increase in bleeding events. Therefore, aspirin is likely 
doing more harm than good in most patients, leading clinicians to start recommending to 
discontinue aspirin use for primary prevention [18]. 
1.3.2 P2Y12 Inhibitors 
For very high-risk patients (i.e. ACS and patients with stent placement) dual antiplatelet 
therapy (DAPT) or aspirin and a P2Y12 inhibitor is recommended. P2Y12 inhibitors differ 
from aspirin in that they block ADP-induced platelet activation. By blocking the P2Y12 
receptor of platelets, ADP induced activation of GPIIb/IIIa does not occur. 
The most common P2Y12 inhibitor is clopidogrel, also known as Plavix. Clopidogrel 
is a pro-drug, and as such requires metabolic activation by cytochrome P450 (CYP). 
However, it has become evident that there is a significantly variable response to clopidogrel 
within the patient population. It has been identified that polymorphisms in the CYP2C19 
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allele that codes for the CYP metabolite leads to variants that are unable to metabolize the 
pro-drug. Therefore, upwards of 30% of the population will not benefit from the 
antithrombotic effects of clopidogrel [22]. Additionally, the CHARISMA (Clopidogrel for 
High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) 
clinical trial found that DAPT of Plavix and aspirin did significantly reduce the risk of 
MACE [23].  
Three additional P2Y12 inhibitors have been developed as next generation. Prasugrel 
employs a different metabolic pathway than clopidogrel which should lead to more 
effective platelet targeting. Ticagrelor and cangrelor are direct P2Y12 inhibitors that bind 
to the protein without metabolic activity. Each of these drugs has gone through a clinical 
trial for comparison to clopidogrel efficacy and safety. Prasugrel was found to reduce 
ischemic events over clopidogrel in the TRITON-TIMI trial but was associated with 
significantly more bleeding. Ticagrelor reduced the occurrence of MACE over clopidogrel 
use but was still associated with an 11.2% bleeding rate in the PLATO trial. Finally, 
cangrelor was not found to be superior to clopidogrel in the CHAMPION clinical trial [22]. 
Therefore, while improvements in efficacy are being made for P2Y12 inhibitors, bleeding 
remains a significant issue. 
1.3.3 GPIIb/IIIa Inhibitors 
The final group of antiplatelets is the GPIIb/IIIa inhibitors. These drugs are 
intravenously administered and act by direct interaction with the GPIIb/IIIa membrane 
protein on platelets, thereby inhibiting strong adhesion of platelets to vWF and subsequent 
aggregation [24]. Two inhibitors of interest in this group are eptifibatide and abciximab. 
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Eptifibatide was assessed in the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable 
Angina: Receptor Suppression Using Integrillin Threapy) trial and found to reduce the rate 
of myocardial infarction from 15.7% to 14.2% over the placebo group. However, the risk 
of bleeding more than doubled (14.1% vs. 6.0%) with the use of eptifibatide [25]. 
Abciximab, which acts similarly to eptifibatide, presented similar efficacy and bleeding 
results in the RAPPORT and ADMIRAL clinical trials [26]. 
1.4 Current Platelet Function Tests 
Given the balance needed between efficacy and bleeding risk, a reliable laboratory 
assay to predict responsiveness to a particular drug and dose is needed. A diagnostic 
assessment is useful in this context, and several methods have been developed to test 
platelet function in response to antithrombotic therapy. Thus, these types of diagnostic tests 
have been generally named as Platelet Function Tests (PFTs). This section will detail 
current methods for determining platelet function, detailing the strengths and shortcomings 
of each method in the clinical setting. 
1.4.1 Light Transmission Aggregometry (LTA) 
LTA was first developed in the 1960s by Born and O’Brien as a methodology for 
measuring platelet aggregation [27, 28]. This was originally noted by each of these 
researchers independently after ADP was added to platelet rich plasma (PRP) and a visible 
change in the opacity of the solution was observed. It has become the gold standard for 
testing platelet function [29]. 
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LTA is conducted by preparing a PRP sample by centrifuging whole blood and 
isolating the PRP supernatant off of the red blood cell rich pellet. The PRP sample is then 
pipetted into a cuvette heated to 37°C and stirred with a small magnetic stir rod. Agonists 
(i.e. ADP, ristocetin, thrombin, or collagen) are added into the PRP sample in order to 
activate platelets. The light transmission of the sample is recorded as the platelets begin to 
aggregate and precipitate out of solution. 
The advantages of LTA include the simplicity of the platelet aggregation endpoint, the 
ability to test multiple agonists for multiple platelet functions (i.e. platelet-platelet and 
platelet-protein interactions), and the depth of clinical studies that show that LTA can 
diagnose platelet and bleeding disorders [30].  
However, disadvantages of the method include the laboratory workup that is needed to 
create PRP from whole blood, which takes time and manpower. Additionally, the stirring 
of the sample may skew results, as there is not a standard stir speed in every lab that 
conducts the LTA test [29]. Therefore, methodologies that are more automated and robust 
may provide more clinical utility than LTA. 
1.4.2 Chrono-Log Whole Blood Analyzer 
The Chrono-Log Whole Blood Analyzer determines platelet function by impedance 
aggregometry. Impedance aggregometry is the measurement in the changes of electrical 
impedance between two metal electrodes due to the build-up of a substance layer on them. 
In this case, that substance is platelets from a whole blood sample. The overall process of 
testing impedance aggregometry with the Whole Blood Analyzer is very similar to that of 
the LTA described previously, with the exception of using a whole blood sample rather 
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than a PRP sample. 500 µL of blood is placed into an equal volume of saline within a 
cuvette and heated for 5 minutes to a temperature of 37°C. This sample is also stirred with 
a small magnetic stir bar and an electrode is placed in the sample. Once the electrode is 
able to establish an impedance baseline, an agonist is added to the blood sample and 
continuously stirred to adequately mix. As platelets begin to become activated and stick to 
the electrode surface, the impedance readout rises. The impedance aggregometer then 
provides three values of Lag Time (the time between agonist addition and for the 
impedance to rise above 2 Ω, the Amplitude (the maximum change in impedance over the 
whole reading), and the Area Under the Curve (AUC, the integral of the impedance over 
time).  
Advantages of the Whole Blood Analyzer is that the user is able to test with a whole 
blood sample rather than PRP as in the LTA, which cuts down on sample processing time. 
Additionally, this system offers a multichannel setup, which increases the throughput of 
the device as the user is able to run multiple samples at once. Finally, it is overall cost 
effective with the base unit approximately $7,000 and the costs to run each test on the order 
of a few cents. 
However, there are disadvantages of the Whole Blood Analyzer. One disadvantage is 
that the electrodes need cleaned after each assessment, and if this is not properly done then 
the endpoints may be skewed. This lack of cleaning automation or single-use 
cartridge/electrode system limits the ability of the aggregometer to make reliable 
assessments clinically. Additionally, the test does not incorporate physiological flow 




The VerifyNow® is perhaps the most commonly used PFT diagnostic in the clinic since 
it began being marketed in the late 1990’s. This device takes the concept of LTA and 
modified it with two big advantages: use of whole blood and complete automation. 
The method involves testing a 1 mL sample of citrated whole blood in a cartridge 
including a relevant agonist for the assessment (i.e. ADP for P2Y12 inhibitors and 
arachidonic acid for aspirin). Glass beads that are in the disposable cartridges of the 
VerifyNow® test are coated with the agonist. Once mixed with whole blood, the light 
transmission through the glass beads is changed as platelets begin aggregate and coat the 
surfaces of the glass beads (Figure 1-1A). A single light transmission reading is provided 
after 2-5 minutes of mixing blood with the beads and reported as either ARU (“aspirin 
response units”) or PRU (“P2Y12 Reactivity Units”). Cut-off values for both ARU and 
PRU have been determined for platelet activity. 
Clinically, VerifyNow® has been used extensively, in particular for the PRU test with 
clopidogrel. Two trials in particular have shown that the VerifyNow PRU test was 
significant in for MACE occurrence in patients with high vs. low PRU values (235 cut-
off). One study of 380 patients undergoing percutaneous coronary intervention (PCI) 
showed that patients with higher PRU values, indicating high P2Y12 activity, had a 
significantly higher occurrence of MACE. The other study included 683 patients with acute 
coronary syndrome and showed similar significant results of MACE occurrence with PRU 
values [31, 32]. 
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However, The GRAVITAS (Gauging Responsiveness With a VerifyNow Assay-
Impact on Thrombosis and Safety) trial of 5,429 patients on dual antiplatelet therapy 
(DAPT) failed to predict differences in MACE between experimental groups [31]. It also 
showed that VerifyNow was not able to predict optimal doses of clopidogrel for patients, 
which is part of the goal of PFTs for directed individualized therapy.  
Advantages of VerifyNow® are that it is a fully automated system that utilizes very 
small sample volumes for its assessment. This allows for a standardized procedure from 
laboratory to laboratory, so results can be effectively compared. Some studies also indicate 
it may have some predictive value in MACE occurrence, although this is not demonstrated 
in every clinical assessment with VerifyNow. 
There are some very significant disadvantages with the use of VerifyNow, as well. 
Most significantly is that the system lacks the pathological hemodynamics of arterial 
thrombosis, namely a high shear environment. Additionally, the agonists that are utilized 
in the VerifyNow diagnostic are not relevant agonists in the pathological scenario where 
sub-endothelial collagen promotes vWF-platelet aggregation. The test is also rather 
expensive, with each individual cartridge costing the clinical laboratory ~$60 and 




Figure 1-1. (A) VerifyNow cartridge concept of light transmission aggregometry with 
agonist coated beads (blue) and platelets (red) [33]. (B) PFA-100 concept where blood 
is aspirated through a membrane orifice coated with agonists to promote platelet plug 
formation.  
1.4.4 PFA-100® 
Platelet Function Analyzer-100 (PFA-100®) is the first clinical PFT diagnostic to 
incorporate high shear flow into its analysis. The system is described as having shear rates 
between 4,000 and 6,000 s-1, which are in the pathological range. The PFA-100® makes 
use of a membrane orifice coated with fibrillar type I collagen and epinephrine (C-EPI) or 
ADP (C-ADP) (Figure 1-1B). First, 800 µL of blood is loaded into the cartridge and the 
aspirated upward through a capillary tube. The blood then enters a second chamber, where 
it comes into contact with the coated membrane and is forced through the small 100 µm 
hole that is coated with collagen and epinephrine or ADP. A platelet plug begins to form 
and occludes the hole in the membrane, leading to the endpoint of closure time (CT) or 
non-closure (NCT) if the test takes longer than 300 seconds. 
The PFA-100 has been extensively used in research of the effects of clopidogrel, 
aspirin, and GPIIb/IIIa inhibitors. However, PFA-100 has not been able to reliably show 
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inhibition by antiplatelets like aspirin and clopidogrel using both the C-EPI and C-ADP 
cartridges, and therefore has not gained much traction in the clinic. Assessments with the 
PFA-100 found that patients non-responsive to aspirin were 2.1 times more likely to 
experience MACE; however, 24.8% of patients responsive to aspirin per the PFA-100 still 
experienced MACE [34-36]. Therefore, the specificity of PFA-100 is poor. 
The disadvantages of PFA-100® are the lack of shear prior to the orifice, which creates 
a sudden flow contraction. The orifice dimensions would be critical for shear rate, but the 
paper membrane is not geometrically stable under pressure and shear stress. Thus, the 
geometry of the test section is not anatomically relevant to the case of a stenotic artery. The 
system apparently does not work with only collagen coating. Thus, the required additions 
of epinephrine or ADP to the membrane also create a non-physiologic scenario, where only 
collagen would be present to initiate vWF and platelet adhesion. While the introduction of 
high shear flow is certainly a step in the right direction, changes to these factors are likely 
necessary to better recapitulate the pathophysiologic conditions of high shear arterial 
thrombosis. 
1.4.5 Global Thrombosis Test (GTT) 
The Global Thrombosis Test was developed by researchers in the UK with the aim of 
creating a high shear PFT that does not utilize any anticoagulation, thus testing non-treated 
blood. GTT recreates a physiologic-like flow scenario with relevant shear accelerations 
across a double ceramic ball-bearing system (Figure 1-2) [37, 38]. GTT utilizes two 
endpoints of occlusion time and thrombolysis time as determined by a drop-based 
photosensor. Occlusion time is defined as the point at which time between drop readings 
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is greater than 10 seconds. Thrombolysis time is the time for another drop to occur after 
occlusion time, following a 300 second thrombus stabilization period. Correlations 
between thrombolysis time and MACE have been observed, with a sensitivity of 60% and 
specificity of 80% [38]. No correlations have been found with occlusion time. 
 
Figure 1-2. Schematic of the Global Thrombosis Test cartridge for high shear 
thrombosis testing. Blood is injected into a test tube and flows past two ceramic balls 
in series that create areas of high shear. Thrombi form and occlude these channels 
between the ceramic ball-bearings and the tube, leading to an occlusion time (OT) 
metric. Once flow is detected again, the system reports a lysis time (LT) [37].  
However, the lack of both a pro-thrombotic surface and any anticoagulation provides 
some skepticism in the endpoints of this assay. The ceramic flow-contacting surfaces lack 
any surface coating, such as collagen, to promote thrombus formation. In addition, the test 
is performed on non-anticoagulated whole blood immediately after blood draw. While 
there is obvious upside to testing native blood samples, the histology of the clots from the 
GTT show significant fibrin and few platelets suggesting thrombosis from contact 
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activation instead of vWF-platelet aggregation that is the sine qua non of arterial white 
clots [39].    
1.4.6 Microfluidic Assays 
With the advances and benefits (smaller samples, faster assays) of microfluidic 
technologies for biological applications over the last 20 years, many experimental 
microfluidic assays have been developed for the study of platelet thrombus formation [40-
43]. I will detail a few significant ones that inspired this work: 
Platelet adhesion studies. Several groups have investigated platelet function with a 
simple straight channel design and a collagen coated surface. A significant group in this 
research field is the Diamond Lab at the University of Pennsylvania. They have created a 
reversible bonding microfluidic technology where they collagen coat a 1000 µm thick strip 
perpendicular to the main flow path, which acts as the pro-thrombogenic “landing zone” 
for platelets to adhere [44]. Blood is drawn from 8 inlet reservoirs converging into a single 
outlet, allowing for the simultaneous testing of 8 different blood samples or treatments. As 
the blood passes over the collagen surface, platelets begin to adhere. However, this single 
channel system is designed to only assess platelet adhesion at shear rates of ~1,000 s-1, 
which a normal arterial flow conditions and not as pathophysiologic. As a result, the assay 
is only useful in assessing platelet adhesion, not bulk platelet thrombus aggregation. 
Another group has developed an automated well-plate straight channel microfluidic called 
Bioflux. The procedure requires the fluorescent labeling of platelets and imaging with a 
fluorescent microscope. While it may provide the same outcomes as the other platelet 
adhesion studies, it comes at a significant cost of ~$80,000 for the Bioflux flow control 
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equipment and compatible fluorescent microscope. Not only is this type of system 
expensive, but it also requires a skilled microscopy technician to conduct the assessment 
and is not suitable for the clinical diagnostic setting. 
Shear-gradient studies. Others have investigated the importance of geometric changes 
leading to flow accelerations, or shear gradients, on the formation of arterial thrombi in 
microfluidics. In particular, microfluidic studies from the Nesbitt lab at Royal Melbourne 
Institute of Technology compared the formation of platelet thrombi in straight channel 
systems and those with constricted, or stenosed, channels to simulate an atherosclerotic site 
[45]. The straight channel studies indicated significant platelet adhesion, but unstable bulk 
thrombus formation. The microfluidic channels that introduced shear gradients through a 
2D constriction developed stable platelet thrombi, indicating that flow accelerations may 
play a role in the formation of arterial platelet aggregates. Therefore, straight channel 2D 
microfluidic systems may not be a suitable method for investigating platelet aggregation. 
T-TAS. The Total Thrombus-formation Analysis System (T-TAS) was developed by a 
lab at Kagoshima University as a flow-based microfluidic system for generating arterial 
platelet thrombi. The system makes use of a single inlet reservoir and single outlet for 
pressure readouts. The test section of the cartridge is split into 25 microchannels coated in 
collagen, each of a 40 x 40 µm cross section. Blood flows through the microchannels at a 
shear rate of 2,000 s-1 and goes through a shear gradient acceleration as it enters the test 
section. This system seems promising as a potential high shear arterial thrombosis 
diagnostic, but does raise a few questions. First, the shear rate is above normal arterial flow 
conditions, but not high enough (> 5,000 s-1) for stable platelet-vWF capture [14]. 
Additionally, the dimensions of the device channels are very narrow that emphasizes 
 18 
collagen wall capture more than rapid platelet accumulation on vWF from mural platelets.  
This device is intriguing and it will be interesting to see future clinical results from this 
group. 
3D Stenosed Microfluidics. As detailed above, most geometries are two-dimensional 
(2D) in design, meaning no variation in the z-direction of the channel [42]. This leads to 
the small height of channels being continuous throughout and not just in the test section 
zone, leading to high resistances and the need for a pump to drive flow. Our group has 
previously investigated the ability to make microfluidic stenoses in the z-direction, thus 
decreasing overall resistance and allowing for gravity to drive flow through the channels. 
Li et al developed a 4-channel system with a shear gradient leading to a stenotic test zone 
using a vertical milling machine [46]. While this method was able to create high shear 
arterial thrombi, the relatively large dimensions of the device (250 x 750 µm cross-section 
at the stenosis) were more “milli-fluidic” than microfluidic, requiring a significant volume 
of blood to reach thrombotic occlusion. Therefore, Casa et al investigated CNC 
micromachining to create microfluidics of channel heights on the order of 70-80 µm. While 
this approach was successful at achieving lower blood volumes per test (~2-5 mL), the 
repeatability of channel dimensions was inferior to standard lithography practices. The 
dimensional variability leads to variable shear rates. This led to high variability > 30% in 
the endpoint of channel occlusion time (OT), as platelet accumulation rates are dependent 
on shear rate [47]. An integration of 3D geometries with enhanced dimensional 
repeatability is still necessary for arterial thrombosis assays. 
1.5 Hypotheses and Specific Aims 
 19 
 Currently, clinicians are unable to quantifiable determine if their patients are 
responding adequately to their prescribed antiplatelet medication. This is due to the lack of 
a reliable platelet function diagnostic, which should provide insight into individualized 
responses to therapies. As such, clinicians are prescribing therapies based on risk factors 
and are blind to the actual effectiveness until an adverse event occurs, either by ineffective 
therapy (i.e. myocardial infarction or stroke) or overly effective therapy (i.e. bleeding 
complications). This shows that there is a need for both improved diagnostic tools and 
antithrombotic therapies in order to decrease the rates of adverse events. To aid in the 
development of better diagnostics and more reliable antithrombotic therapies, we aim to 
answer the following questions: 
• Can we leverage highly repeatable lithography practices and collagen coating 
techniques to create a more repeatable microfluidic thrombosis assay? 
• Do current anticoagulation methods of platelet function tests have a significant 
impact on the endpoint of platelet thrombosis? 
• Will a less variable assay effectively determine responses to antiplatelet therapies 
that does not correlate to other PFTs that have proven unreliable? 
• Can a low-variability, high shear microfluidic assay be utilized to screen for more 
effective antithrombotic therapies? 
Therefore, the overall goal of this work is to develop a low variability stenotic microfluidic 
thrombosis assay (MTA) that has the able to detect individualized antiplatelet efficacy in 
the clinical setting, as well as provide a metric by which to test novel antithrombotic 
therapies in the research setting. 
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This work has three primary aims: 
Specific Aim 1: Reduction of microfluidic thrombosis assay (MTA) variability 
through design factors.  
I hypothesize that the main sources of variability observed in previous microfluidic 
thrombosis assays are due to three fundamental design factors: geometric variability, 
collagen coating, and anticoagulant selection. To improve geometric precision in current 
stenotic microfluidic assays, a novel 3D grayscale lithography method will be developed 
for improved dimensional repeatability. Collagen surface coverage with collagen thin films 
will be compared to standard fibrillar coatings. Lastly, the most common anticoagulant 
utilized in PFTs (citrate – a calcium chelator) will be compared to an anticoagulant against 
thrombin (low-dose heparin). 
Specific Aim 2: Assess the ability of the MTA to quantify antiplatelet responsiveness.  
I further hypothesize that the endpoint of occlusion time in a low-variability assay 
will provide diagnostic utility for individual antiplatelet responsiveness. To assess the 
clinical utility of the microfluidic assay developed in Aim 1, a specificity study to 
antiplatelet therapy will be performed for aspirin and clopidogrel. Samples from healthy 
individuals will be assayed pre-treatment and post-treatment to determine the assay 
specificity to antiplatelet responsiveness. A comparative study of acute coronary syndrome 
(ACS) patients prescribed either aspirin or DAPT will then be performed against two other 
PFTs: GTT and VerifyNow PRU test. 
Specific Aim 3: Development of a novel nanoparticle antithrombotic therapy.  
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Finally, I hypothesize that such a device can be utilized to develop novel 
antithrombotic nanoparticle therapies. To create a potentially more efficacious 
antithrombotic therapy, nanoparticles of differing sizes, surface groups, and doses will be 
assessed in the microfluidic assay. An optimal particle and dose will be determined and 
assessed in a murine arterial thrombosis model for in vivo safety. 
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CHAPTER 2. SHEAR INDUCED PLATELET AGGREGATION: 
3D-GRAYSCALE MICROFLUIDICS FOR REPEATABLE AND 
LOCALIZED OCCLUSIVE THROMBOSIS 
Results detailed in this chapter have been reported in BioMicrofluidics [48]. 
Abstract 
 Atherothrombosis leads to complications of myocardial infarction and stroke as a 
result of shear-induced platelet aggregation (SIPA). Clinicians and researchers may benefit 
from diagnostic and benchtop microfluidic assays that assess thrombotic activity of an 
individual. Currently there are several different proposed point-of-care diagnostics and 
microfluidic thrombosis assays with different design parameters and end-points. The 
microfluidic geometry, surface coatings, and anticoagulation may strongly influence the 
precision of these assays.  Variability in selected end-points also persists, leading to 
ambiguous results. This study aims to assess the effects of three physiologically-relevant 
extrinsic design factors on the variability of a single end-point to provide a quantified 
rationale for design parameter and end-point standardization. Using a design of 
experiments approach, we show that the methods of channel fabrication and collagen 
surface coating significantly impact variability of occlusion time from porcine whole 
blood, while anticoagulant selection between heparin and citrate did not significantly 
impact variability. No factor was determined to significantly impact the mean occlusion 
time within the assay. Occlusive thrombus was found to consistently form in the first 
section (333 µm) of the high shear zone and not in the shear gradient regions. The selection 
of these factors in the design of point-of-care diagnostics and experimental SIPA assays 
may lead to increased precision and specificity in high shear thrombosis studies. 
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2.1 Introduction 
Myocardial infarction and ischemic stroke are the leading causes of death in the 
world [49]. Both morbidities occur as the result of an atheroma causing a stenosis in 
the coronary and carotid arteries with resulting pathophysiological high shear blood 
flow. If there is a plaque cap rupture causing endothelial damage, then a rapid 
formation of a platelet-rich clot ensues [2, 3, 50]. Rapid platelet accumulation can 
grow until occlusive thrombus forms, stopping blood flow in the artery. An assay to 
quantify a patient’s propensity for stenotic thrombosis would significantly aid in the 
personalized titration of antiplatelet medications to prevent myocardial infarction 
and stroke occurrence while reducing bleeding complications. However, current 
clinical and microfluidic systems suffer from high inter- and intra-subject variability 
causing poor specificity from a test with low precision [51-53]. 
2.1.1 Failings of platelet function tests 
Several platelet assays are available for testing platelets, including VerifyNow®, 
Chrono-log Whole Blood Aggregometer, and Light Transmission Aggregometry 
(LTA), PFA-100®, and GTT [34]. Only the PFA-100® and GTT test for platelet 
response under flow. The other three systems (VerifyNow®, Chrono-log, and LTA) 
test platelets under stirring conditions rather than shear flow, which is not 
appropriate for making conclusions regarding arterial thrombosis. Nevertheless, 
VerifyNow® is the most common platelet assay used clinically [51]. The 
GRAVITAS (Gauging Responsiveness With a VerifyNow Assay-Impact on 
Thrombosis and Safety) trial of 5,429 patients on aspirin and Plavix® dual 
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antiplatelet therapy (DAPT) failed to show statistical differences in death rates due 
to major adverse cardiovascular events (MACE) between patients with high and low 
P2Y12 reaction units (PRU) as determined by the VerifyNow® assay, thus 
supporting the claim that VerifyNow® is not suitable to predict patient outcomes 
[31]. This is likely partially due to the finding that intra-individual variation of the 
VerifyNow® assay is considerably high, with 25% of individuals having greater 
than a 20% coefficient of variability (CV) between measurements. This caused 24% 
of individuals to fluctuate between therapeutic categories between measurements 
[54, 55]. 
Of the flow-based assays, PFA-100® is used far more than the relatively new 
GTT, with more than 600 studies published in peer-reviewed journals. PFA-100® 
makes use of a membrane orifice coated with fibrillar type I collagen and 
epinephrine or ADP. This orifice creates an area of high shear flow through a sudden 
flow contraction that is not hemodynamically relevant to the case of an 
atherosclerotic, stenotic artery. The additions of epinephrine and ADP to the 
membrane also create a non-physiologic scenario, where only collagen would be 
present to initiate von Willebrand Factor (vWF) and platelet adhesion. This is 
associated with poor predictive value, as 24.8% of patients responsive to aspirin per 
the PFA-100® still experienced MACE [34-36]. Like VerifyNow®, PFA-100® has 
high intra-individual end-point variability between 17-37%, which may prevent its 
clinical utility [56, 57]. 
In response to the failings of platelet function tests, several experimental 
microfluidic assays have been developed for the study of shear induced platelet 
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aggregation (SIPA); however, there remains variability upwards of 35% in the 
outcomes of SIPA microfluidic assays [40-43, 53]. In 2011, the biorheology 
subcommittee of the International Society of Thrombosis and Haemostasis made 
recommendations on four experimental design parameters for the standardization of 
flow-based thrombosis assays: microfluidic geometry, surface coatings, 
anticoagulation, and end-point imaging [58]. While these recommendations have 
been documented for nearly a decade, no specific parameter grouping has been 
proven to reduce end-point variability within SIPA microfluidics. Therefore, a 
parametric comparative study is needed to determine the effects of each of these 
parameters on variability. 
2.1.2 Microfluidic Thrombosis Assay Design Parameters 
Most geometries are two-dimensional (2D) in design, meaning no variation in the 
height of the channel. While they have highly repeatable dimensions via lithography 
techniques, these channels suffer in two major ways. If there is no variation in the 
width along the channel, then there is a lack of shear gradient important for plasma 
vWF elongation. Also, for more complex and longer channels there is a high 
resistance due to the small channel heights that must be overcome through increasing 
the pressure driving flow, as resistance is inversely proportional to the height cubed 
(Equation 2-1). While this can be accomplished with a pump, undesirable high 
pressures will develop in the channels as full occlusion forms. Further, utilizing a 
pump creates a constant flow situation, rather than constant pressure. With constant 
flow, a single-inlet, multiple-outlet microfluidic device (Figure 2-2) would skew 
flow from a more high resistance channel to a lower resistance channel, thus each 
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channel is dependent on the thrombotic activity in the other channels. This flow 
compensation skews results, as blood flow is diverted depending on resistance of 
the parallel channels. A constant pressure system, however, allows for thrombotic 
events to occur independently across channels, as flow independently decreases for 
a given channel as resistance increases due to thrombus formation. This is due to 
flow being driven by the same pressure difference. Pressure remains constant, 
resistance rises, and flow decreases in that channel. Flow in other channels will not 
be affected, as they are governed by their own changes in resistance. Therefore, it is 
important to be able to establish geometric variations in the height to limit high-
resistance areas in the test section of the microfluidic, allowing for constant pressure 
flow systems. While computer numerical control (CNC) micromachining has been 
used previously for three-dimensional (3D) microfluidic applications, the 
repeatability of channel dimensions is inferior to standard lithography practices. The 
dimensional variability leads to variable shear rates, therefore increasing the 
channel-to-channel variability. An integration of 3D geometries with enhanced 
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Pro-thrombogenic surface coatings for high shear thrombosis assays have been 
investigated significantly in the last two decades [59-61]. While fibrillar type I 
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collagen is the most common in the field due to the specific binding of vWF to 
collagen fibers [62], the deposition of fibers into flow channels leads to sparse and 
non-uniform surface coverage [60]. Exploration into soluble collagens has indicated 
highly uniform surface coverage, but a significant decrease in platelet response due 
to the lack of structural fibers [63]. One study investigating vWF-III combined with 
collagen-mimetic peptides GFOGER and CRP and another study of 52 different 
natural and synthetic coatings investigated platelet accumulation response under 
flow, and found that several of the coating combinations had enhanced surface 
coverage, but fibrillar type I collagen led to the strongest thrombotic response under 
normal arterial shear [64, 65]. Focusing on enhancing the repeatability of fibrillar 
collagen coatings, Hansen et al induced fiber formation from acid-soluble collagen 
in order to develop collagen thin films (CTF) [60]. While there was success in 
achieving high fiber density and coverage, the standard fibrillar coating still had a 
significantly stronger platelet response in terms of faster adhesion. However, the 
impact of increased fiber density and coverage on end-point variability, such as 
platelet adhesion and aggregation, was not assessed. 
Anticoagulation is utilized to keep blood from clotting between the draw and the 
test due to contact activation upon introduction to foreign substances, such as the 
blood collection containers. There have been a range of different anticoagulants used 
in various assays. Differential effects on platelets based on anticoagulant selection 
indicate that this choice may impact end-point variability [40, 42, 66]. A commonly 
utilized anticoagulant in clinical and research applications is sodium citrate [34, 67, 
68]. Sodium citrate chelates calcium in whole blood, which is a co-factor for several 
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steps of the coagulation cascade and platelet activation as integrins are sensitive to 
calcium ion levels [66, 69]. It has also been reported that vWF requires calcium for 
platelet adherence, which suggests recalcification is needed prior to testing [70]. 
However, recalcification to a concentration of 10-40 mM prior to testing often leads 
to rapid coagulation of the sample during the experiment if not performed on-chip 
[71]. Methods for on-chip addition of calcium may not mix well with the citrated 
blood sample due to low Reynold’s number flow. Further, it has also been reported 
that citrate irreversibly reduces the reactivity of platelets and impairs αIIbβ3 
activation even after recalcification [40, 52]. Another anticoagulant option, heparin, 
acts to increase levels of antithrombin II to inhibit thrombin cleavage of fibrinogen, 
and is the most commonly used short-acting anticoagulant in clinical settings [72]. 
Heparin presents the benefit of no secondary recalcification step leading to rapid 
contact activation of the coagulation cascade, making it easier to work with after the 
blood draw. Some studies suggest that heparin may inhibit P-selectin function in 
platelets and their α-granules, which could prevent vWF release during the rapid 
platelet accumulation phase [40, 73]. Heparin is also reported to potentially have an 
impact on the thrombin-platelet interaction, but not directly on the vWF-platelet 
interaction [74]. 
Finally, imaging of the thrombus development is vital in the determination of an 
assay end-point through a non-blood contacting method. However, discrepancies in 
the location of thrombus formation within a stenotic test section are found in the 
literature. Two different stenosis test sections created thrombus growth in the 
downstream shear-gradient zone of the channel [45, 75]. However, other reports 
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indicate that thrombus formation occurs within the stenotic zone [46, 76, 77]. The 
location of occlusive thrombus in a stenosis with an anatomically relevant throat 
needs confirmation for the design of a thrombosis imaging end-point. 
2.1.3 Objectives and hypothesis 
This study aims to assess the main sources of variability of in vitro microfluidic 
SIPA assays. It is hypothesized that current sources of variability are associated with 
extrinsic factors of channel geometry, pro-thrombotic collagen coverage, and 
anticoagulant selection. Reducing dimensional and surface coverage variation, as 
well as use of anticoagulation that does not greatly impair GPIIb/IIIa activation will 
greatly decrease variability associated with the end-point of thrombotic occlusion 
time. Further, control of these three factors will lead to a spatially consistent 
occlusive thrombus within the physiologically relevant 3D microfluidic geometry. 
2.2 Methods 
2.2.1 Microfluidic Geometry Fabrication 
Microfluidic geometries were designed in order to keep platelet-platelet interactions 
dominant over platelet-surface interactions [41]. Therefore, the minimum stenotic height 
was set at 70 µm to ensure platelet-platelet aggregation was being studied. The dimensions 
of the nominal channel sections were determined by CFD estimations (COMSOL 
Multiphysics, COMSOL Inc.) to establish normal arterial shear rates of 500 s-1, while 
stenotic arterial shear rates in the test section were designed to be 6,500 s-1. Two methods 
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of device fabrication were investigated for geometric repeatability and effect on end-point 
variability: CNC machining and 3D grayscale laser-lithography (GLL). 
First, a brass mold was machined with a CNC machine (ProtoTRAK, Southwestern 
Industries, Inc.). The stenotic geometries were created with a series of mill events. Eight 
nominal channel segments were fabricated to be 180 µm in height and 475 µm in width 
with a 1.0 mm milling tool with 2 passes with coolant, as Z feed-rate of 50 mm/min, XYZ 
feed-rate of 300 mm/min and spindle speed of 150,000 RPM. Stenoses at a height of 80 
µm with gradual contraction zones like an atheroma were created from the nominal 
channels with two cut events from the center of the stenosis to make the upstream and 
downstream contraction zones. This was completed with the 1.0 mm milling tool using the 
parameters previously described. 
The GLL method was developed to take advantage of highly repeatable lithography and 
etching processes (Figure 2-1), and the development methods are described in detail in 
Appendix A. In brief, 100 mm silicon wafers were coated with approximately 5.0 µm of 
photoresist (Microposit SC1827, MicroChem) and variably exposed with ultraviolet light 
with the use of direct laser writing (Laserwriter LW405, Microtech) to develop defined 
contraction zones in the photoresist. The wafer was developed to remove exposed 
photoresist (MF-319, MicroChem). A Bosch etch process (STS ICP) was used to etch the 
stenotic profile into the exposed silicon wafer to a depth of 180 µm from the wafer surface, 
followed by an acetone wash of remaining photoresist. A 10 µm photoresist layer (AZ 
P4620, MicroChemicals) was then spray coated (AltaSpray Coater, SUSS MicroTec), 
followed by a mask alignment process to align the nominal device geometry on the wafer. 
Finally, another Bosch etch process was performed to a target nominal depth of 250 µm, 
 31 
leaving the stenotic height at 70 µm above the wafer surface. A total of four test channels 
were fabricated for a single inlet (Figure 2-2). Quality control measurements at all 
fabrication steps were acquired through contact profilometry (Dektak, Bruker). 
 
Figure 2-1. Process flow for the development of the novel 3-D 'grayscale' lithography 
technique. Linear variations in the z-direction were made possible through this 
method to establish contracting stenotic zones mimicking an atheroma. 
Microfluidic chips were created by casting PDMS (Sylgard 184, Krayden) on both 
machined and lithography molds. PDMS channel height measurements were made with 
3D material confocal microscopy (LEXT, Olympus). Average and standard deviation of 
nominal and stenotic heights, as well as arithmetical mean height (Sa) for surface 
roughness, were calculated for both methods. 
2.2.2 Collagen Surface Coating 
Two methods of collagen coating were investigated for coverage repeatability and effect 
on end-point variability: fibrillar and collagen thin films (CTFs).  The fibrillar coating 
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method was described previously by Casa et al, where microfluidic channels were filled 
with a 100 µg/mL collagen Type I solution in 0.9% saline (Chronopar, Chronolog, Inc.) 
and incubated at room temperature for 24 hours [3]. The second method of CTF coating 
was described by Hansen et al, where microfluidic channels were filled with a 1000 µg/mL 
soluble collagen solution neutralized with 0.1N NaOH and diluted with PBS [60]. In this 
experiment, however, the collagen was incubated at room temperature for 24 hours prior 
to washing and drying. 
Characterization of collagen surface coverage was performed by light microscopy 
(DM6000B, Leica Microsystems) with a 20X objective. Acquired RGB images were 
converted to grayscale, followed by 55% threshold binary images (MATLAB, 
MathWorks). The image was divided into equal quadrants and the percent coverage was 
calculated in each area. The average and standard deviation of the collagen coverage was 
calculated for both fibrillar and CTF coatings. 
2.2.3 Anticoagulation 
Whole porcine blood (N = 6) was obtained from a local abattoir (Holifield Farms, 
Covington, GA) and split into two jars with either unfractionated heparin or sodium citrate 
so that identical blood samples were utilized in both conditions: 
1) 500 mL of porcine whole blood was lightly heparinized at 3.5 USP units/mL, as 
previously described by Para et al [77]. Blood was stored at room temperature on a 
rocker prior to testing. 
2) 450 mL of porcine whole blood was treated with 50 mL of 3.2% sodium citrate 
(weight percentage in aqueous solution) and stored at room temperature on a rocker 
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prior to testing. Blood was recalcified with CaCl2 to a final [Ca
2+] of 10 mM 
immediately prior to each experiment. 
All whole blood experiments were performed within 6 hours after blood collection. 
2.2.4 Microfluidic Thrombosis Assay 
The collagen-coated microfluidic chips were positioned on the stage of a light 
microscope (DM6000B, Leica Microsystems) with a 4X objective (40x magnification) and 
connected to an upstream reservoir with Tygon tubing, similar to that previously described 
(Figure 2-2) [3]. A constant pressure head (100 mmH20) is established for an initial wall 
shear rate of 6500 s-1 in the stenotic zone and 500 s-1 in the nominal channels. Downstream 
tubing led to a discharge reservoir placed on a precision balance (Ohaus Scout SPX222, 
Ohaus Corp) to measure mass flow rates. Images of thrombus formation were acquired at 
1 Hz with a high-resolution CCD camera (Pixelfly, PCO). Image acquisition was facilitated 
by the µManager open-source microscopy software [78]. Occlusion time (OT) was 
measured as the time from first blood contact with the stenosis to the time of the initial 
maximum mass reading. 
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Figure 2-2. Microfluidic SIPA assay setup with gravity driven pressure from an 
upstream syringe. Blood samples are split evenly between 4 stenotic test section zones 
and independent mass accumulation readouts from precision electronic balances are 
sampled at 1 Hz via a National Instruments DAQ. Real time visualization is also 
performed and recorded at 1 Hz with a PixelFly camera. 
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Table 2-1. Fractional Factorial Experimental Groups for the three main design 
factors of geometry fabrication by CNC or GLL, collagen coverage with fibrillar or 
CTF, and anticoagulation with heparin or citrate. 
Group Geometry Collagen Anticoagulant 
A CNC Fibrillar Heparin 
B CNC CTF Citrate 
C GLL Fibrillar Citrate 
D GLL CTF Heparin 
 
A total of four experimental groups were assessed in a fractional factorial 
design of experiments, described in Table 2-1. Four blood samples were tested in 
quadruplicate for each test group, while two additional blood samples had 3 final 
replicates due to a leak or blockage eliminating one of the four microfluidic 
channels. The average OT was calculated and standard deviation was determined. 
Percent variance was determined by dividing the standard deviation by the average 
occlusion time. 
2.2.5 Image Analysis 
Images of the stenotic channel gathered by the CCD camera were assessed 
for location of occlusive thrombus growth. Images were segmented into five 
regions: 1) inlet gradient, 2) first third of stenosis, 3) middle of stenosis, 4) last third 
of stenosis, and 5) outlet gradient. At the end of a thrombotic experiment, the 
intensity of platelet deposition was recorded for each region to determine relative 
rates of platelet accumulation. 
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2.2.6 Statistical Analysis 
 All variability calculations for channel geometry, collagen surface coverage, 
and occlusion time were performed by dividing the standard deviation by the mean 
of replicate measurements. Student’s t-test was calculated for channel dimension, 
collagen surface coverage, and clot region measurements. ANOVA was utilized to 
calculate the f-statistic for each model parameter (geometry, collagen, and 
anticoagulant) in order to determine each parameter’s significance on occlusion time 
variability [79]. All statistical analyses were performed with JMP Pro (SAS Institute, 
Inc., Buckinghamshire, England). 
2.3 Results and Discussion 
2.3.1 Chip Geometric Precision 
Assessment of geometric precision of both techniques (CNC and GLL) was 
performed with the LEXT material confocal microscope and summarized in Figure 2-3. 
For 2D geometric zones (flat along the z-direction) of the channel, the GLL technique 
proved to have superior precision over the CNC method. However, the GLL yielded 
surface roughness of 18.9 µm in the sloping geometric zones that ramped into and out of 
the stenosis, with a periodic peak-to-value distance of 18.8 µm on average. This compares 
to a surface roughness of 2.3 µm in the CNC ramped zones. As for the stenotic zone, 
surface roughness of 0.7 µm and 1.3 µm were measured for the GLL and CNC, 
respectively. The increased roughness in the GLL ramps is likely due to the resolution of 
the LaserWriter step prior to the Bosch process, as any defect in the photoresist layer will 
be amplified in the silicon mold due to the etch rates of the two materials (depicted in 
 37 
Figure 2-1 steps 1-3). Thus, the two techniques have distinctly different strengths, with the 
GLL giving precise depths, while CNC machining yields smoother ramps.  While the 
surface roughness of the lithography method is not desirable, the heights and effective 
shear rates in the nominal and stenotic GLL test sections were consistent to 0.2% within 
an individual channel and across channels. In contrast, the standard deviation of the stenotic 
heights in the CNC channels was measured to be 2.9 µm, which led to a 3.5% variability 





Figure 2-3. LEXT confocal 3-D images of (A) CNC machined and (B) GLL 
lithography microfluidic channels. (C) Linear profiles indicate the heights of the 
channels in the nominal and stenotic regions, as well as overall surface roughness 
characteristics. GLL proved superior in geometric repeatability in the stenotic zone, 




Table 2-2. Assessment of fabrication technique dimensional variability for both CNC 
and GLL methods. 
 Stenotic Height (µm) Nominal Height (µm) 
Method Target Actual Variability Target Actual Variability 
CNC (n=8) 80.0 82.4 ± 2.9 3.5% 180.0 182.6 ± 2.6 1.4% 
GLL (n=4) 70.0 73.7 ± 0.1 0.1% 250.0 256.0 ± 0.4 0.2% 
 
For our purposes, shear rate in the throat was the dominant factor for the thrombosis 
endpoint.  The wall shear rate in a rectangular channel is dependent on the height squared, 
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Therefore, with highly repeatable nominal and stenotic heights, the precise lithography 
channels will have more repeatable flow and shear rates from channel-to-channel. This was 
confirmed in a water flow rate comparison, where flow rate variability in CNC channels (n 
= 8) was determined to be 11.7%, while GLL channel (n = 4) variability was determined 
to be 4.0%. 
2.3.2 Collagen Surface Coverage 
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Collagen surface coverage was determined through light microscopy using a 
20X objective and segmentation of the focal area to assess spatial variability in 
coverage. Qualitatively, fibrillar coatings led to random and sparse deposition of 
fibers, while the CTF coat provided much more uniform and dense coverage (Figure 
2-4). This analysis confirms that similar CTF coatings were utilized in this 
experimental protocol as those utilized by Hansen et al in comparing CTFs with 
fibrillar collagens in the strength of platelet adhesion response [60]. Quantitatively, 
the surface coverage of CTFs was determined to be more dense and uniform than 
fibrillar coatings, as shown and discussed earlier (Figure 2-4F). Although the CTF 
coating was previously studied extensively and found to not exhibit as strong a 
platelet adhesion response as fibrillar type I collagens, the increased and more 




Figure 2-4. Collagen coating assessment performed on fibrillar coatings (A-B) and 
CTFs (D-E) by light microscopy. Collagen is identifiable in the deep orange colored 
areas of A and D, which is then converted to a binary distribution map based on the 
pixel values. (A) indicates much longer, but more sparse collagen type I fibrils, while 
(D) shows the deposition of microfibrillar CTFs over most of the surface. Images are 
converted to binary format and divided into quadrants (C). Percent surface coverage 
of each quadrant was calculated and averaged for both conditions (F). All 
microphotographs are to the same scale. 
2.3.3 Occlusion Time Variance: Fractional Factorial DOE 
The multi-parameter design of SIPA microfluidic assays requires an end-point 
variability analysis to provide guidelines to consider in the future design of such tools. This 
Design of Experiments can identify the dominant versus secondary factors influencing the 
endpoint, occlusion time. Therefore, an occlusion time variance analysis was performed 
for the three design parameters of interest: fabrication technique, collagen coverage, and 
anticoagulation selection.  
Occlusion time was determined for each of the four experimental groups for six 
porcine samples, from which variance was calculated (Figure 2-5). Immediately, group C 
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(GLL, fibrillar, and citrate) had the least variability in the end-point of occlusion time at 
11.5% on average. However, the group analysis was then followed by assessment of each 
parameter within the experimental design by a standard least squares effect screening.  
 
Figure 2-5. Experimental data of average occlusion time (N = 3 or 4) for each sample 
within each group. The coefficient of variance was calculated by dividing the standard 
deviation by the average OT and is shown here for each sample. Group C (GLL, 
fibrillar collagen, citrate anticoagulation) led to the least variability in the occlusion 
time endpoint as compared to groups A (CNC, fibrillar, and heparin), B (CNC, CTF, 
citrate), and D (GLL, CTF, heparin). The fractional factorial design ANOVA 
revealed that GLL geometry (p < 0.01) and fibrillar collagen coating (p < 0.05) are 
significant parameters in reducing assay variability. No significant difference was 
found in assay variability between citrate and heparin anticoagulation. Dashed lines 
are the mean coefficient of variability and whiskers are the standard deviation of that 
mean. 
First, the parameter that had the largest impact on occlusion time variability was 
the geometry fabrication technique (Figure 2-5; p < 0.01). The microfluidic chips 
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fabricated by GLL led to a significantly more repeatable end-point. As previously stated, 
shear rates were more consistent between channels, leading to similar rates of platelet 
thrombus formation. This is consistent with previous work studying and predicting rates of 
platelet accumulation [14, 80]. This finding also indicates that the surface roughness 
associated with the contracting zones of the grayscale lithography technique do not greatly 
impact the end-point of the assay. While the surface roughness could be improved upon, 
the repeatability of the shear-rates in the nominal and stenotic sections of the channel make 
GLL a more attractive option than CNC machining methods. 
Fibrillar coatings also were found to significantly decrease variability of the 
thrombosis assay end-point over the use of CTFs, although to a lesser extent than the 3D 
fabrication method (Figure 2-5; p < 0.05). This was contrary to our hypothesis that a more 
uniform collagen fiber surface coverage would lead to less variable end-points. Apparently 
vWF and CTFs associate weakly, as previously observed in platelet adhesion assessments 
[60, 63]. These weak interactions may lead to more random adhesion of vWF onto the CTF 
surface, thus causing the increase in end-point variability. Even though deposition is non-
uniform in the flow channel, type I fibrillar collagens lead to a more stable and reliable 
vWF interaction, which is likely the reason for the decreased variation [62, 63]. 
Finally, no significant difference was found in the use of unfractionated heparin 
(3.5 USP) or sodium citrate (3.2%) anticoagulation methods in reducing occlusion time 
end-point variability for porcine whole blood (Figure 2-5). However, from a practical 
experimental approach, it is beneficial to utilize heparin in the assay as coagulation is not 
a major factor for the short time scale of SIPA microfluidics (3-5 minutes) and at high 
shear rates. Recalcification of the citrated whole blood samples can lead to large clots in 
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the inlet reservoir and tubing, making this technique difficult to manage. Coagulation was 
observed in several of the recalcification experiments and made timing very important to 
develop platelet-rich clots before RBC-rich clots obstructed the flow pathway. While this 
timing could be reduced by methods of on-chip recalcification, this is generally impractical 
when performing this experiment. Further, in future experiments evaluating antiplatelet or 
thrombolytic therapies, SIPA experiments will take more time and be more susceptible to 
coagulation occurring and blocking flow before a complete assessment of platelet 
thrombosis can be made. While the combination of GLL, fibrillar collagen, and heparin 
was not part of the DOE analysis, this combination yielded an end-point variability of 
11.6% (N = 4), which was consistent with the finding of Group C in the DOE. Therefore, 
it is simpler to utilize an anticoagulant like unfractionated heparin for SIPA microfluidic 
assays, where no additional steps for recalcification are required.  
Parameter selection did not play a significant role in the time to occlusion. For the 
geometric differences, this is not surprising as Para reports that in the late stages of 
thrombus formation, rapid platelet accumulation (RPA) occurs rapidly to overwhelm 
variations in initial surface height [77]. Therefore, the 10 µm difference in channel heights 
between CNC and GLL methods did not play a significant role in quantifying occlusion 
time. What is surprising, however, is that the collagen coating method was not found to 
significantly impact occlusion time in this assay. With previous reports stating that fibrillar 
collagen coatings provide a stronger response to platelet adhesion, it might be expected 
that fibrillar coatings lead to significantly shorter occlusion times. While a small decrease 
in occlusion time was associated with fibrillar coatings, it was not significant over CTF 
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coatings. Anticoagulant selection had no significant impact on the time to occlusion within 
the microfluidic assay. 
2.3.4 Spatial Repeatability of Thrombus Formation 
Finally, we performed an analysis on the spatial occurrence of SIPA thrombotic 
formation within the microfluidic assay. After occlusive thrombus was formed, the final 
images were segmented into five regions of converging, stenotic thirds, and diverging 
zones (Figure 2-6). Intensity values of the white-clot regions were recorded (n = 8). 
We observed that the occlusive platelet clot was consistently formed in the first 
third of the stenotic channel (p < 0.01), while significantly less clot formation was observed 
in the shear-gradient converging and diverging zones (p < 0.01). This is consistent with 
our findings that GLL methods have less variability in occlusion time than CNC methods. 
GLL provides superior control of the geometry in the stenotic section of the channel, where 
the occlusive platelet clot forms. The occlusive clot does not form in the gradient sections 
of the channel, which indicates that the increased surface roughness in those zones by the 
GLL method does not significantly impact the endpoint. However, this finding is not 
consistent with a previous report that found platelet accumulation most at the diverging 
outflow region of the channel [45]. The differences between the previously reported results 
and ours are likely due to: 1) the prior’s lack of collagen and reliance on protein absorption 
to the PDMS walls to promote platelet accumulation and 2) the very small area at the top 
of their stenosis. Theoretically, the absorption of vWF would be less likely to occur in the 
high shear zone due to a decreased residence time in these zones. However, when utilizing 
collagen as in the current case, vWF fibers in high shear zones tether to the physiologically 
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relevant surface with more avidity and repeatably form occlusive thrombus in the first third 
of the channel. 
 
 
Figure 2-6. Segmentation of the microfluidic channel into 5 regions of interest: 1) 
converging gradient, 2-4) thirds of the stenotic zone, and 5) diverging gradient. The 
first third of the converging zone was found to always develop the occlusive thrombus 
(p < 0.01), as shown in the mean intensity analysis of each zone and the bottom 
representative image of occlusive thrombus. Dashed lines represent the mean 
intensity and whiskers are the standard deviation of the mean. (Results in 
collaboration with Dongjune Kim [48]) 
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 The relative influence of the factors studied here may prove beneficial in the general 
design of point-of-care whole blood assays. By designing a shear-activated test section for 
repeatable platelet thrombosis formation, a microfluidic assay can be globally coated with 
collagen rather than locally coated through specialized collagen coating techniques that 
require critical alignment techniques [53, 61]. Development of an optical detection system 
for clot formation in a limited stenotic zone would allow for an alternative end-point for 
platelet clot formation when determining thrombotic risk of a patient. Eventually, this type 
of SIPA microfluidic assay may provide more physiologically relevant results for arterial 
occlusions than current PFTs in use. 
2.3.5 Limitations and future work 
 Though effective in determining geometric and collagen coating parameters for 
decreasing occlusion time endpoint variability of the microfluidic thrombosis assay, this 
work is limited by several fundamental shortcomings. First, this work was performed with 
porcine whole blood rather than human whole blood. While porcine whole blood is 
considered to be fairly similar to that of humans, blood plasma protein sequences do differ 
slightly between the species, which may alter the time it takes for a platelet thrombus to 
occlude the channel. While this may not have a highly significant impact on an 
investigation of assay variability, it would dispel any questions regarding its translation to 
humans if human whole blood had been utilized. 
 An additional limitation is that the rough, scalloped surfaces developed in the 
converging and diverging zones of the GLL manufacturing method. While we show that 
variability of the assay is not highly dependent on the surface roughness of the gradient 
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zones since the thrombus forms in the constant high shear region, it may limit the level of 
method adoption due to researchers being averse to the scalloped nature. Therefore, future 
work into grayscale techniques such as the subtractive manufacturing technique developed 
in this thesis (see Appendix A) or additive grayscale techniques may benefit the adoption 
of this type of microfluidic channel. 
 Lastly, this study only investigated two options for each parameter (geometry, 
collagen surface, and anticoagulation), while there certainly are more than two approaches 
to tackle each challenge. This study does not claim to have found the optimal “end-all, be-
all” best approach, but rather shows design choices that are proven to limit assay 
variability. Future methods, such as enhanced fibrillar collagen coatings, were not 
investigated in this work but may also contribute to decreasing assay variability. 
2.4 Conclusion 
We quantified the relative importance of several methodological parameters on 
end-point variability in SIPA microfluidic assays.  Two design parameters 
(geometric fabrication technique and collagen coating method) have significant 
impact. The development of a 3D grayscale laser lithography technique creates 
stenotic test sections of precise geometry and enhanced shear rate repeatability, as 
compared to current CNC machining methods for 3D channel fabrication. Fibrillar 
collagens were also found to significantly reduce end-point variability as compared 
to a collagen thin film coating approach, even though the fibrillar coating was non-
uniform in surface coverage. Anticoagulation method did not impact variability in 
the SIPA of porcine whole blood. Finally, it was determined that clot formation 
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consistently occurred in the first 0.3 mm of the stenotic channel with a constant 
pressure head, providing a basis by which to design optical detection methods in 
SIPA point-of-care diagnostic devices. 
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CHAPTER 3. DIAGNOSTIC POTENTIAL OF THE 
MICROFLUIDIC THROMBOSIS ASSAY 
Abstract 
 Platelet function tests (PFTs) have the potential to assess antiplatelet efficacy and 
the risk for major adverse cardiovascular events (MACE) on an individualized basis. 
However, no current clinical PFT provides significant predictive value for MACE 
occurrence. We have previously developed a microfluidic thrombosis assay (MTA) that 
incorporates the major causes of arterial thrombosis: high shear blood flow, collagen pro-
thrombotic surface, and significant blood components platelets and vWF. This study 
characterizes the MTA for its ability to assess antiplatelet function in both healthy and 
patient populations and compare the patient population to outcomes of two other PFTs: 
GTT and VerifyNow. Healthy individuals pre- and post-aspirin (N = 20) show that aspirin 
significantly extends MTA occlusion time (OT) and also shows that blood anticoagulated 
with sodium citrate has a greater effect on platelet function compared to blood 
anticoagulated with unfractionated heparin. Significant correlations were found when 
comparing MTA and GTT OT in patients on aspirin (ρ = 0.699; p < 0.001; N = 20), but no 
correlation was found between the two assays in patients on DAPT (ρ = 0.482; p = 0.07; N 
= 15). No other correlations were found between the MTA and other PFTs. The findings 
of this study indicate that the MTA assesses a different platelet thrombosis mechanism than 
current PFTs and is less sensitive to the effects of antiplatelet therapies, which may prove 
a more specific assay for predicting MACE. 
3.1 Introduction 
3.1.1 Antiplatelets for arterial thrombosis 
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To prevent adverse thrombotic events from occurring, therapies targeting platelet 
activation and adhesion have been utilized for over 50 years. Two of the most common 
therapies are aspirin and clopidogrel (also known as Plavix). Aspirin acts by irreversibly 
inhibiting COX-1, which interferes with thromboxane synthesis. This inhibition prevents 
activation from platelets by thromboxane production [81]. Plavix is formulated to 
irreversibly inhibit the P2Y12 platelet ADP receptor, thus permanently inhibiting another 
platelet activation pathway [82]. However, both drugs may not work as intended for the 
entire population, as various studies have reported up to 5-60% of individuals are hypo-
responsive to therapy, thus exhibiting an “antiplatelet resistance” depending on the study 
and drug regimen [35, 36, 51, 83-86]. Dual antiplatelet therapy (DAPT) consisting of 
aspirin and a P2Y12 inhibitor (usually Plavix) is often employed to overcome antiplatelet 
resistance [51]; however, this may lead to an increase in primary side effects, with 7.4% 
incidence of fatal and nonfatal bleeding among individuals on DAPT [87]. The observed 
complications to standard doses of leading antiplatelet agents proves the need to 
individualize antiplatelet therapy through diagnostic screening with a platelet function test 
(PFT). 
3.1.2 Platelet function test comparison 
A PFT may ideally be utilized to quantify a patient’s propensity for arterial 
thrombosis and provide a means for personalized titration of antiplatelet medications to 
prevent MACE occurrence while reducing bleeding complications. In the previous chapter, 
we detailed the development and characterization of the microfluidic thrombosis test 
(MTA) with reduced endpoint variability from previous versions in our laboratory. The 
MTA incorporates specific design inputs to mimic the pathophysiological condition of 
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arterial thrombosis: 1) pathological high shear blood flow (>5,000 s-1) [2], 2) flow channel 
dimensions greater than 50 µm for platelet accumulation to dominate over platelet surface 
adhesion interactions [41], 3) collagen as a relevant agonist for circulating vWF capture 
[13, 88, 89], and 4) anticoagulant selection to prevent coagulation from occurring without 
significant effects on platelet function [40]. By incorporating these parameters, the MTA 
simulates the physiologic scenario better than the most common PFT, VerifyNow. 
VerifyNow lacks relevant biophysical stimuli in its test, relying solely on biochemical 
agonists to detect platelet function. Another PFT, GTT, only incorporates biophysical 
stimuli in its test without any biochemical agonist (i.e. collagen). The MTA incorporates 
both high shear and a collagen pro-thrombotic surface in determining platelet function. 
We now aim to characterize the utility of the MTA device design in identifying 
antiplatelet responsiveness in individuals taking antiplatelet medication.  
3.1.3  Objectives and hypothesis 
 We now aim to test the MTA, as compared to VerifyNow and GTT, in the 
assessment of the effects of antiplatelet therapies aspirin and Plavix in both healthy subjects 
and cardiovascular patient populations. In order to study these effects, we designed a study 
to determine the MTA’s specificity to detect the effects of aspirin therapy in a healthy 
population by assessing pre- and post-therapy occlusion time. Through this study we are 
able to determine normal OT’s and a cut-off for therapy responsiveness with the MTA. We 
are then able to employ this cut-off OT value in a patient population study to compare the 
MTA with VerifyNow and GTT. It is hypothesized that therapy responsiveness determined 
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by each PFT will have poor correlation with one another, indicating that each PFT is 
investigating different clotting phenomena. 
3.2 Methods 
3.2.1 Materials 
Polydimethyl-siloxane (PDMS) was from Krayden, Inc. (Denver, CO, USA). Type I 
collagen was from Chrono-Log (Havertown, PA, USA). Testing of the MTA was 
performed on a Leica DM6000B microscope from Leica Microsystems, Inc. (Buffalo 
Grove, IL, USA), along with Scout SPX222 balances from OHAUS Corporation 
(Parsippany, NJ, USA) for mass flow rate detection and a high-resolution CCD PixelFly 
camera from PCO (Kelheim, Germany) for image acquisition. The VerifyNow® (VN) unit 
from Accriva Diagnostics, Inc. (San Diego, CA, USA) is housed at the clinical lab in Grady 
Memorial Hospital (Atlanta, GA, USA). The GTT unit from Thromboquest Limited (UK) 
is housed at the Georgia Institute of Technology (Atlanta, GA, USA). 
3.2.2 Blood testing procedures 
Microfluidic Thrombosis Assay (MTA). The microfluidic channels were fabricated 
by gray-scale lithography techniques previously described [48]. Fibrillar type I collagen-
coated (100 µg/mL)  microfluidic chips are positioned on the stage of a light microscope 
with a 4X objective and connected to an upstream reservoir with Tygon tubing, similar to 
previously described [3]. Downstream tubing leads to a discharge reservoir placed on a 
precision balance to measure mass flow rates. Images of thrombus formation are acquired 
at 1 Hz with a high-resolution CCD camera. Image acquisition is facilitated by the 
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µManager open-source microscopy software [78]. Occlusion time (OT) is measured as the 
time from first blood contact with the stenosis to the time of the initial maximum mass 
balance reading. Image and flow-rate post-processing was performed with custom code 
(MATLAB, MathWorks). 
VerifyNow® (VN). VN is a PFT that assesses platelet reactivity under low-shear 
by light transmission. The P2Y12 reaction units (PRU) cartridge is utilized in this study. A 
blood sample collected into a 3.2% sodium citrate 3mL vacutainer is assayed in the 
cartridge. A PRU value less than 235 indicates drug-induced platelet dysfunction [54, 55]. 
Global Thrombosis Test (GTT). The GTT is a PFT that assesses platelet thrombus 
formation and lysis under flow conditions [37, 39, 90]. A single cartridge with two ceramic 
ball-bearings that create 3 flow-channel gaps is utilized to develop a clot and detect lysis 
by a drop counter. One 6mL, nonanticoagulated blood sample is injected into the cartridge 
from a syringe. Occlusion times between 300 and 500 seconds represent normal hemostatic 
activity, while those faster than 300 seconds indicate platelet hyper-reactivity and those 
longer than 500 seconds indicate effective therapy. Lysis times earlier than 2000 seconds 
indicate normal spontaneous thrombolytic activity, while those greater than 2000 seconds 
indicate low thrombolytic activity. 
Complete Blood Count (CBC). A CBC was taken for all healthy individuals 
participating in the study and recorded from previous lab exams for cardiovascular patients 
participating in the study. 
3.2.3 MTA Specificity Study 
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Healthy volunteers were older than 18 years of age, had no history of cardiovascular 
disease, and had taken no antiplatelet medication (aspirin, Plavix, etc.) nor non-steroidal 
anti-inflammatory drugs (NSAIDS; i.e. ibuprofen) in the 10-days prior to enrollment. 
Individuals with known anemia (hematocrit < 30%) or transmittable blood diseases were 
excluded. The MTA was the only PFT utilized in this proof-of-concept study. All subjects 
were recruited in accordance with the Institutional Review Board of the Georgia Institute 
of Technology (IRB #H18238). 
 First, the MTA was assessed in an initial group of eight individuals at two different 
time points a week apart, prior to beginning aspirin treatment. This assessment was 
performed with either 3.2% sodium citrate (the most common anticoagulant choice of 
PFTs) or 3.5 USP unfractionated heparin (an indirect thrombin inhibitor) vacutainers to 
determine the effects of anticoagulant selection on inter-week variation of the MTA. 
 The main study cohort then consisted of 20 healthy adults not currently taking 
antiplatelet, anticoagulant, nor NSAIDS therapy. Prior to starting an aspirin regimen, 39 
mL of blood were drawn from each subject using standard phlebotomy practices with a 
21G butterfly needle: 18 mL in 3.2% citrate tubes, 18 mL in 3.5 USP heparin tubes, and 3 
mL in an EDTA tube for a complete blood count (CBC). Each subject then began a low-
dose aspirin regimen (81 mg/day) for 1-week. This regimen was chosen as it is the standard 
dose prescribed for antiplatelet effects and it has been previously reported that the effects 
of aspirin therapy on platelets are prevalent after one week of sustained therapy [91]. After 
taking aspirin on the final day of the week-long regimen, another blood draw of 39 mL was 
performed. All blood samples were tested within 4 hours after venipuncture. The 
percentage of aspirin responders was determined based on the cut-off OT time determined 
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in baseline pre-aspirin measurements. Intra-draw variability of the MTA was also assessed 
from this group of individuals. Correlations between OT and CBC values were determined. 
3.2.4 PFT Comparison Study 
The study cohort for a population-based study consisted of 35 adults (18 or more 
years of age) admitted to Grady Memorial Hospital for an interventional procedure in the 
Catheterization Lab. Subject recruitment was in accordance with the Institutional Review 
Board of Emory University and Research Oversight Committee of Grady Memorial 
Hospital (IRB #00106933). 20 individuals were on aspirin therapy as the only prescribed 
antiplatelet as part of their care, while another 15 individuals were on DAPT of aspirin and 
Plavix. The following exclusion criteria were used in patient recruitment: inability to 
consent, current participation in another study, cardiogenic shock, sepsis, malignancy, 
bleeding diastasis, thrombolysis therapy, warfarin therapy, GPIIb/IIIa inhibitor therapy, or 
blood dyscrasia [38]. Demographics (age and gender) were collected from patient records 
after consent was obtained. MTA and GTT were assessed for all subjects in this cohort, 
while VerifyNow PRU was assessed only for subjects on DAPT. 
After consent was obtained and during the catheterization procedure, 20 mL of 
blood was collected from either the radial or femoral artery insertion site: 2 mL initial 
discard, 12 mL for the MTA (6 mL treated with 3.2% sodium citrate and 6 mL treated with 
3.5 USP unfractionated heparin), 2 mL for VerifyNow PRU test (treated with 3.2% sodium 
citrate), and 4 mL for GTT (no anticoagulant). A CBC was already on file for each patient. 
All blood samples were tested within 4 hours after collection, except the GTT sample 
which was tested immediately after draw without anticoagulation per the manufacturer’s 
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instructions. The percentage of responders per the MTA were determined based on the 
cutoff metric calculated in the healthy population study, while responders per VerifyNow 
and GTT were determined from the manufacturer’s set ranges. Correlations of endpoints 
in all three PFTs with CBC values were also determined. 
3.2.5 Statistical analysis 
 Continuous variables of occlusion time, lysis time, and PRU are presented as mean 
± standard deviation. Normality of each dataset was determined by the Shapiro-Wilk test 
for data sets of small sample size (N < 50) [92]. Intra-day and inter-day variation in MTA 
OT were determined using student’s t-test. The cut-off point for the MTA was set as two 
standard deviations above the healthy individual pre-aspirin OT to determine antiplatelet-
effectiveness. Nonparametric analyses for paired (Wilcoxon test) and unpaired (Mann-
Whitney test) were used for the healthy and patient subject populations, respectively. For 
non-normal data sets simple correlation between tests was assessed with Spearman 
correlation coefficients (ρ), where perfect correlations are represented by ρ of +1 or -1 [93]. 
Agreement between assays for determining “antiplatelet resistance” was assessed with 
Cohen’s Kappa statistic (κ), where κ < 0.20 indicates no agreement, 0.21-0.40 as mild, 
0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1 as almost perfect agreement 
[94]. Correlations between assay endpoints and CBC values were determined by 
multivariate correlation probability (p < 0.05). Statistical analysis was performed in either 
GraphPad Prism (San Diego, CA, USA) or JMP Pro (Marlow, Buckinghamshire, UK). 
3.3 Results 
3.3.1 MTA inter-day variability: heparin vs. citrate 
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First, variability in the MTA OT endpoint was assessed in this protocol to investigate 
the inter-day variability for heparin and citrate anticoagulation. This was a follow-up to the 
previous chapter that investigated intra-day variability, only. 3.2% sodium citrate and 3.5 
UPS unfractionated sodium heparin were utilized for comparison in a standard 
venipuncture blood draw with vacutainers. Variability results are represented in Figure 
3-1. Variability datasets were tested for gaussian distribution by the Shapiro-Wilk test and 
were determined to be normally distributed. Intra-day variability for blood collected in 
citrate and heparin vacutainers was 16.6% and 11.8% (N = 17; p = 0.15), while inter-day 
variability was 19.7% and 7.2% (N = 8; p < 0.05), respectively. No significant difference 
was found between the two anticoagulants for intra-day variability, which is consistent 
with the results of the previous aim. However, it was determined that inter-day (or week-
to-week) variability was significantly less with 3.5 USP heparin vacutainers over 3.2% 
sodium citrate vacutainers. 
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3.3.2 MTA Specificity Study: Low Dose Aspirin 
Prior to starting individuals on aspirin therapy, baseline measurements of occlusion 
time in the MTA were determined for both citrate and heparin treated blood. This provided 
a population mean and standard deviation in OT for the 20 healthy subjects studied. A cut-
off of 300 seconds (dashed line in Figure 3-2) was calculated from this population data set 
as two standard deviations above the mean in both citrate and heparin groups. The cut-off 
OT represents the point at which an individual is defined as responsive (> 300s) or non-
responsive (< 300s) to antiplatelet therapy. This point is applied to any antiplatelet therapy 
Figure 3-1. Comparison of intra-day (left) and inter-day (right) coefficient of 
variation of the MTA OT with blood samples collected by venipuncture with either 
3.2% sodium citrate or 3.5 USP unfractionated heparin vacutainers. Intra-day 
measurements were taken from the same blood draw and tested in separate 
microfluidic cartridges (N = 17; p = 0.15). Inter-day measurements were taken from 
blood draws of the same donor on separate days to assess variability of different time 
points (N = 8; p < 0.05). Each data point is an average of 4 OT measurements within 
the MTA, represented by the dashed line with standard deviation. *p < 0.05 
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as it marks a significant inhibition of thrombus formation above the average population 
value of the MTA. 
 
Figure 3-2. Summary of the healthy population week-long drug regimen 
characterization in the MTA. (A) Occlusion time population data of pre- and post-
aspirin (ASA) when collected in citrate or heparin vacutainers. A cut-off of standard 
occlusion times was determined as two standard deviations above the baseline 
average and is depicted as the dotted line at 300s. Both post-aspirin groups are found 
to be statistically different than their respective pre-aspirin condition, indicating that 
aspirin impacts OT for the population. Log-normal distributions for OT were 
observed in both (B) citrate and (C) heparin collection methods. (N=20; Each data 
point is the average of 4 or 8 OT measurements in the MTA; *p < 0.05; **p < 0.01; 
***p < 0.001) 
 
After week-long aspirin therapy, individuals were assessed of their thrombotic state 
with the MTA. Aspirin therapy was determined to have a significant effect on OT 
measurements in the MTA for both citrate (p < 0.001) and heparin (p < 0.01), as calculated 
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by a Wilcoxon test for nonparametric, log-normal datasets. A significant difference in 
responder rates was also found between the anticoagulation methods, as 10/20 (50%) 
individuals were aspirin responders when collected in citrate tubes, while only 2/20 (10%) 
individuals were aspirin responders when collected in heparin tubes (p < 0.01). Three 
individuals’ samples did not register an OT by 900s when treated with citrate 
anticoagulation, at which point the test was terminated. Both individuals who were 
responders with heparin treated blood were also responders with citrate treated blood. The 
Cohen’s Kappa correlation coefficient between these two anticoagulant methods was 
0.200, indicating weak agreement between the two methods. The rate of occurrence of 
individual occlusion times is also reported for both anticoagulants in Figure 3-2, where 
log-normal distributions are depicted. The effects of aspirin are detailed on an individual 
subject basis for citrate and heparin in Figure 3-3. The heat map of OT’s for each condition 
(pre and post aspirin treatment collected in either heparin or citrate) indicates the level of 
aspirin-responsiveness, with darker green indicating highly responsive and darker red 
indicating highly non-responsive (completely white being the 300 s OT therapeutic cut-
off). From this heat map and the dot plot, only 2/20 individuals in the heparin group had a 
faster OT after aspirin. Comparably, only 1/20 individuals in the citrate group had a faster 
OT after aspirin. This plot is also a good demonstration of the significant differences in 
PFT outcomes based on anticoagulant selection. From clinical data, it is expected that 
aspirin will not have a very significant role in preventing shear-induced platelet 
aggregation. This is better reflected in the heparin anticoagulated data, where only minor 
individualized differences in OT are observed. Large differences in OT are observed in the 
citrate group, indicating that citrate may be assisting aspirin in altering platelet function. 
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Therefore, heparin will be used over citrate as the MTA anticoagulant in the following 
studies.  
 
Figure 3-3. Summary of the individualized data week-long drug regimen 
characterization in the MTA. (A) Sorted by OT values of the Post-Aspirin Heparin 
(second column). Individual data of occlusion time pre- and post-aspirin (ASA) when 
collected in citrate or heparin vacutainers. Green indicates responsive to therapy, 
while red indicates non-responsive on the heat chart. Individual tracking of the OT 
data from pre-treatment to post-treatment when collected in (B) heparin and (C) 
citrate also indicates a general increase in OT on an individualized basis. Aspirin is 




3.3.3 Aspirin responsiveness: MTA vs. GTT 
16 cardiology patients undergoing an interventional catheterization procedure on 
aspirin as their only antiplatelet therapy were assessed with the MTA and GTT platelet 
function tests. The MTA reported an aspirin response in 3/20 (15%) individuals when 
collected in heparin tubes, shown in Figure 3-4. GTT reports both OT and LT during the 
same sampling of nonanticoagulated blood, with 12/20 (60%) aspirin responsive per GTT 
OT and 6/20 (30%) responsive per GTT LT, shown in Figure 3-4.  
 Correlations between the assay endpoints for patients on aspirin as the only 
antiplatelet agent were calculated using both the Cohen’s Kappa test and Spearman 
Coefficient in Table 3-1. A mild correlation was found between the MTA heparin test and 
GTT OT. This is somewhat evident in the heat maps of Figure 3-4. The MTA heat map is 
sorted from most responsive (top) to least responsive (bottom) to therapy, and the 
corresponding samples are matched for the GTT OT and GTT LT heat maps. GTT OT has 
an obvious trend of green toward the top and red toward the bottom, and although not 
perfectly matching the MTA, it indicates a mild correlation per inter-rater correlation Table 
3-1. The correlation between individual data points displayed in Figure 3-5, however, 
shows a significant correlation in the absolute values of the MTA and GTT OT endpoints 
(ρ = 0.699, p < 0.001). This indicates that a high OT determined by the MTA will likely 
have a high OT in the GTT, and vice versa. However, the agreement between the tests for 
the determination of drug responsiveness remains poor (Table 3-1). Poor correlations were 
found between GTT LT and both MTA and GTT OT. 
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Figure 3-4. Summary of the platelet function test endpoint data for patients taking 
aspirin as their only antiplatelet therapy. (A) Population data for heparin 
anticoagulated blood characterized with the MTA. (B) Population data for OT and 
LT of nonanticoagulated blood characterized with the GTT. (C-E) Summary of the 
individual responses for the MTA and GTT, with dark green indicating strongly 
responsive to aspirin therapy and dark red indicating a strong resistance to aspirin 
therapy. Dotted lines across (A) and (B) indicate the cut-off for drug responsiveness 




Figure 3-5. Correlation plots of the MTA, GTT OT, and GTT LT results from the 
patient group taking aspirin only. A significant correlation was observed between the 
MTA and GTT OT, which is highlighted in the red box. No significant correlations 
were observed between any other pairing. Red ellipses represent the 95% bivariate 
normal density confidence interval of the correlation, by enclosing approximately 
95% of the data points. The narrowness of the ellipse reflects the degree of correlation 
of the variables. 
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Table 3-1. Cohen’s Kappa statistic and Spearman Coefficient for agreement of 
aspirin responsiveness in MTA (N=20) and GTT (N=20) platelet function tests. (***p 
< 0.001). 
Cohen’s Kappa (κ) GTT OT GTT LT 
MTA Heparin 0.211 0.028 
GTT OT - 0.074 
Spearman (ρ) GTT OT GTT LT 
MTA Heparin 0.699*** 0.103 
GTT OT - 0.297 
 
3.3.4 Comparison of DAPT response in MTA, GTT, and VerifyNow 
15 cardiology patients undergoing an interventional catheterization procedure on 
dual antiplatelet therapy of aspirin and Plavix were assessed with the MTA and GTT, while 
only 14 of those patients were assessed with the VerifyNow PRU platelet function test. The 
MTA reported a DAPT response in 3/15 (20%) of individuals, shown in Figure 3-6A. GTT 
reports both OT and LT during the same sampling of nonanticoagulated blood, with 12/15 
(80%) DAPT responsive per GTT OT and 5/15 (33%) responsive per GTT LT, shown in 
Figure 3-6B. The VerifyNow PRU test was carried out in 14 of the 15 individuals and 
found 9/14 (64%) were responders to DAPT, shown in Figure 3-6C. 
 Correlations between the assay endpoints for patients on DAPT were calculated 
using both the Cohen’s Kappa test and Spearman Coefficient in Table 3-2. No significant 
correlation per Spearman Coefficient was found between the MTA and GTT OT, which is 
different than the aspirin group above. However, a mild correlation was observed in the 
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inter-rater agreement of the Cohen’s Kappa statistic for MTA and GTT OT. This is further 
evident in the heat maps, where the MTA DAPT is sorted from most responsive to therapy 
(top) to least responsive to therapy (bottom), and all other PFTs are sorted in the same 
patient order. The darker green readings for GTT OT are closer to the top, with the less 
responsive (albeit still light green) are toward the bottom. When comparing the MTA and 
GTT OT, the major difference between the two is the collagen coat vs. the lack of a pro-
thrombotic surface, respectively. The discrepancy in responsiveness rates (MTA = 20%; 
GTT OT = 80%) may be a result of the coating difference. MTA did not have a significant 
correlation with either GTT LT nor VerifyNow. Interestingly, VerifyNow significantly 
correlated with GTT OT in the DAPT group per Spearman Coefficient (ρ = -0.740, p < 





Figure 3-6. Summary of the platelet function test endpoint data for patients taking 
DAPT of aspirin and Plavix. Population data of characterization with the (A) MTA 
with heparin anticoagulation (300s cut-off), (B) GTT OT (500s cut-off) and LT (2000s 
cut-off) without anticoagulation, and (C) VerifyNow PRU test (235 PRU cut-off) with 
citrate anticoagulation. (D-G) Summary of the individual responses for the MTA, 
GTT, and VerifyNow, with dark green indicating strongly responsiveness to aspirin 




Figure 3-7. Correlation plots of the MTA, GTT OT, GTT LT, and VerifyNow results 
from the cardiology patient group taking DAPT. A significant correlation was 
observed between VN and GTT OT, while a significant inverse correlation was 
observed between VN and GTT LT. No significant correlations were observed 
between any other pairing, indicating that the values of the MTA do not correlate 
with either GTT nor VerifyNow for patients taking DAPT. 
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Table 3-2. Cohen's Kappa statistic and Spearman Coefficient for agreement of DAPT 
(aspirin and Plavix) responsiveness in MTA (N=15), GTT (N=15), and VerifyNow 
(N=14) platelet function tests. (*p < 0.05; **p < 0.01). 
Cohen’s Kappa (κ) GTT OT GTT LT VerifyNow PRU 
MTA Heparin 0.118 0.000 0.018 
GTT OT - -0.222 -0.024 
GTT LT - - -0.585 
Spearman (ρ) GTT OT GTT LT VerifyNow PRU 
MTA Heparin 0.482 -0.036 -0.126 
GTT OT - 0.451 -0.740** 
GTT LT - - -0.537* 
 
3.3.5 MTA and CBC correlations 
 For all groups tested, no statistically significant correlations were found between 




Table 3-3. CBC averages for pre- and post-aspirin healthy population (N=20) and 
both patient populations taking either aspirin (N=20) or DAPT (N=15). No 











WBC 5.15 ± 1.64 5.16 ± 1.55 7.02 ± 1.85 6.75 ± 2.33 
RBC 4.92 ± 0.50 4.92 ± 0.52 4.34 ± 0.53 4.52 ± 0.79 
HGB 15.1 ± 1.4 15.0 ± 1.2 12.6 ± 1.0 12.8 ± 2.3 
HCT 42.9 ± 3.9 42.7 ± 3.8 37.7 ± 2.8 38.9 ± 6.6 
MCV 87.5 ± 4.3 87.1 ± 4.0 87.9 ± 7.8 86.5 ± 5.8 
MCH 30.6 ± 1.3 30.6 ± 1.4 29.2 ± 2.7 28.4 ± 2.1 
MCHC 35.2 ± 1.6 35.1 ± 1.8 33.3 ± 0.5 32.9 ± 1.1 
RDW 12.0 ± 1.2 11.9 ± 1.2 14.7 ± 1.2 15.1 ± 1.9 
PLT 234.5 ± 43.0 232.5 ± 41.5 248.6 ± 67.7 238.4 ± 61.7 





This study evaluates the Microfluidic Thrombosis Assay (MTA) for measuring the 
effects of aspirin and DAPT on high shear thrombosis leading to occlusion. The MTA 
incorporates high shear rates similar to an arterial stenosis, and exposure of fibrillar 
collagen similar to a plaque cap rupture using whole blood from human subjects.  The 
MTA demonstrates consistent patterns of occlusive thrombosis in normal subjects and 
patients with coronary heart disease.  Aspirin was able to lengthen the occlusion time in a 
small subset of normal subjects (10%), but did not completely inhibit total occlusion in any 
subjects. This aspirin effect was similar in patients with cardiovascular disease (15%) and 
did not lead to complete inhibition in any subjects. Plavix plus aspirin (DAPT) lengthened 
the occlusion time in a larger subset of patients (20%) and effects with complete prevention 
of occlusion. These ratios of subjects benefiting from aspirin or DAPT is consistent with 
large scale clinical results. 
The use of the MTA for formation of occluding thrombi is affected by the choice 
of an anti-coagulant to allow delayed testing. Heparin is a commonly used anti-coagulant 
that has its primary effect on the coagulation pathway [40]. Its effects on vWF-platelet 
adhesion should be minimal.  Use of heparin led to the fastest occlusion times and the 
smallest intra- and inter-day variability by subject (~11-14%).  Citrate is widely used for 
platelet studies, but is known to affect platelet adhesion, aggregation, and activation  [40, 
51].  Here, citrate led to greater variability and differences in shear induced occlusion from 
heparin. The results also indicated that citrate potentiates the effects of aspirin and Plavix 
on subject responsiveness with a possible worsening of specificity of effectiveness. Thus, 
we do not recommend use of citrate for assays of high shear thrombosis. 
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The MTA results can be compared against the VerifyNow. The MTA showed 
DAPT responsiveness in 3/15 (20%) while VerifyNow showed effectiveness in 9/14 
(64%).  Two of the patients overlapped in effectiveness.  Comparison against VerifyNow 
cutoffs for aspirin effectiveness measures show poor statistical correlation indicating that 
the two devices assay for different effects. 
The MTA results can be compared against the newer Global Thrombus Test (GTT) 
assays of occlusion time and lysis time. The GTT exhibited prolonged occlusion times from 
DAPT in 13/15 (86%) while Lysis Time was shorter for 12/15 (80%).  This is quite a 
different result from the GT-MTA with correspondingly poor correlation. Thus, the MTA 
is clearly measuring different thrombotic mechanisms than the GTT. The occlusion times 
by MTA with collagen are significantly shorter than GTT with ceramic and plastic 
surfaces, even though the shear rate ranges are comparable. This highlights the necessity 
of including both high shear and collagen to mimic arterial thrombotic occlusions.  
3.4.1 MTA aspirin specificity 
Within the healthy population that was tracked before and after week-long aspirin 
therapy, the MTA shows that post-aspirin occlusion times are statistically longer than pre-
aspirin. This demonstrates that aspirin therapy does have an impact on high shear thrombus 
formation. However, this effect is strongly affected by the sample preparation. The findings 
indicate the influence of the choice of anticoagulants. The aspirin response in the healthy 
patient population was found to be significantly different in the MTA when whole blood 
was treated with sodium citrate (50% response rate) vs. heparin (10% response rate). 
Additionally, 3/20 (15%) of normal controls tested did not develop an occlusive clot during 
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the study with a 15-minute endpoint when the blood was treated with sodium citrate, while 
all controls developed an occlusive clot when blood was treated with unfractionated 
heparin. This suggests that sodium citrate has a strong effect on platelet function, which is 
aligned with the interpretation that has been presented in previous literature that platelet 
membrane protein αIIbβ3 is irreversibly altered upon citrate administration [40, 95]. While 
the healthy population pre-aspirin data indicates no significant difference between citrate 
and heparin, there may be a compounding factor in citrate/aspirin interactions in preventing 
platelet adhesion, activation, or accumulation that would explain the significant difference 
in the outcomes of the two anticoagulants post-aspirin. This finding is of significance 
because the two major platelet function tests utilized, VerifyNow and PFA-100, both use 
sodium citrate as an anticoagulant. We have previously mentioned that the current PFTs 
are not designed with the relevant factors for arterial thrombosis, such as high shear and 
collagen surfaces, but now we suggest they also may not be using an appropriate 
anticoagulant in their assessment [48].  
When looking at recent clinical results of the ASPREE and ARRIVE studies 
tracking the clinical outcomes of aspirin use on prevention of major adverse cardiovascular 
events (MACE), it is shown that aspirin does not significantly change outcomes over 
placebo in primary prevention [18-21]. The results presented herein of the MTA with 
heparinized blood may provide support to why aspirin is not useful in the prevention of 
MACE. Although OT was found to be delayed significantly on a population basis, every 
individual still developed an occlusive clot under high shear conditions. This would 
indicate that if an atherosclerotic injury is present in vivo, a clot will likely still develop 
even if aspirin is used. When looking at studies of VerifyNow for assessing aspirin 
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effectiveness with the Aspirin Response Units (ARU) test, aspirin was found to have a  
100% response in individuals [96]. This indicates that the MTA design may be better suited 
for assessing antiplatelet function than VerifyNow. 
3.4.2 MTA OTs in healthy and patient populations 
Comparing the MTA OT data for both the healthy individuals and patients only on 
aspirin antiplatelet therapy, there was no significant difference in the population averages. 
The average OT for the healthy individuals was 227.4s (N=20), while the average OT for 
the patients taking aspirin was 209.3s (N = 20). These two averages are not significantly 
different from one another (p = 0.649), indicating that clotting times are similar across 
healthy and “at risk” populations. Therefore, the patient group is not more “at risk” for a 
cardiovascular event due to their blood biochemistry, but rather another underlying factor 
such as grade of atherosclerotic injury would make them more “at risk”.  
3.4.3 MTA and GTT OT correlation 
Comparisons of the MTA to GTT OT showed a significant correlation in the patient 
population taking aspirin only. The major similarity between the two assays (other than the 
endpoint of OT) is the fact that they both incorporate high shear rates > 10,000 s-1. 
Therefore, they are both using biophysical high shear flow to induce platelet aggregation, 
which is one of the major causes of arterial thrombosis. However, two other major factors 
differ between the tests: methods of anticoagulation (heparin vs. nonanticoagulated) and 
thrombotic agonists (collagen vs. ceramic). These differences may account for why the 
correlation between assay endpoints was no longer significant in the DAPT group, where 
the MTA was more sensitive to DAPT in its OT endpoint. We argue that the MTA 
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accurately simulates the formation of a platelet-rich arterial clot, as the system is designed 
with all three causes of arterial thrombosis in mind: high shear, pro-thrombotic collagen 
surface, and vWF/platelets. In addition, the use of heparin anticoagulation prevents the 
formation of fibrin-rich blood clots from the coagulation cascade. The GTT OT, however, 
does not utilize anticoagulation and may be forming fibrin-rich clots in the recirculation 
zones of the flow channel as a result, but this cannot be verified due to lack of clot 
visualization in the tool. However, it is possible that if the GTT were modified to 
incorporate collagen coating and heparin, the MTA and GTT OT may become nearly 
identical tests and correlate strongly for all therapy groups. 
3.4.4 VerifyNow Correlations with GTT 
As expected due to the lack of major arterial thrombosis causes of high shear flow 
and non-physiological agonists, VerifyNow had very poor correlation with both the MTA 
OT endpoint. However, as mentioned previously in the results, VerifyNow did exhibit 
significant correlation with GTT OT for DAPT patients. This is a peculiar finding, as they 
are very different methods for testing platelet function. GTT OT utilizes high shear flow, 
while VerifyNow mixes blood samples at very low shear. In addition, much of the 
argument for GTT OT is that it does not utilize an anticoagulant, thereby testing fresh 
native whole blood. VerifyNow, on the other hand, uses citrate anticoagulation, which has 
been suggested in this thesis and by other research groups to impact platelet function 
irreversibly [51, 52]. One potential explanation is that both tests may be better suited for 
tested fibrin clotting events, as the GTT group has shown large amounts of fibrin formation 
on the surfaces of these clots and VerifyNow tests in the low shear regime more suitable 
for fibrin-rich clots [90]. Additionally, VerifyNow was found to inversely correlate with 
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the GTT LT metric. Lower VerifyNow values (indicating antiplatelet responsiveness) 
correlated with higher GTT LT values (indicating lack of thrombolytic activity), showing 
further disagreement between PFT methods. 
3.4.5 Testing antiplatelet in vivo vs. in vitro 
In a previous study from our laboratory, aspirin was administered in vitro into blood 
samples and assessed in the “milli-fluidic” MTA model previously described [7]. The 
results of that study showed that addition of aspirin across multiple doses ranging from 0 
to 2.0 mM in whole blood did not significantly change the OT in 5 samples at a shear rate 
of 10,000 s-1. While the OT of the milli-fluidic was higher at the dose of 2.0 mM than at 
baseline, it was not statistically different. This is similar to the assessment presented here 
of testing aspirin after ingestion, as the OT of the MTA was not drastically different than 
the baseline pre-aspirin value and was only statistically different for the population due to 
the higher sample size (N = 20). The same likely cannot be said for Plavix or other 
antiplatelets that must undergo a very complex metabolic pathway to become an active 
drug. In those cases, an in vivo assessment will likely be needed over in vitro administration 
of the drug. However, this comparison of aspirin results indicates that in vitro assessments 
with the MTA may do a suitable job in reflecting how the therapy may perform in vivo. 
3.4.6 Limitations and future directions 
The primary limitation of this study is the small sample sizes in both healthy and 
patient groups. These sample sizes may have limited the power of correlation calculations 
between assays and CBC levels, although CBC levels alone should not dictate antiplatelet 
regimens on an individualized basis. Additionally, having a small sample opens the study 
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to sampling bias and not be representative of a larger population. Another limitation of this 
study is the potential for poor drug compliance, particularly in the patient population that 
was studied. While more checks were in place to determine drug compliance in the healthy 
group taking aspirin, the only check for the patient groups taking aspirin or DAPT was 
verbal confirmation prior to drawing blood. This, however, is a limitation of most drug 
related studies as drug compliance is a major issue not only in research but also in the 
clinical setting. Finally, effects of Plavix alone were not able to be assessed in this study 
as all patients taking Plavix were also taking aspirin (DAPT). Therefore, all outcomes from 
PFTs in the DAPT group cannot be assumed to be the effects of Plavix alone, but rather 
potentially synergistic effects of aspirin and Plavix therapy. 
There are a few future directions for this work. The next step for this research would 
be to plan and initiate a larger clinical study with follow-up to determine the MTA’s ability 
to predict MACE in a patient population. Another “lower hanging fruit” study that may be 
useful to complete is to make modifications to the GTT to incorporate collagen coatings 
and heparin may essentially mimic the MTA. It would be interesting to make those 
modifications and compare the two tests again to see if a stronger correlation exists. 
3.5 Conclusion 
 In summary, the MTA is a rapid assay (<10 min) that requires a small amount of 
whole blood (< 5ml) to create clots in microfluidic channels. The assay can be utilized to 
assess patient propensity to thrombotic occlusion while being treated with aspirin or DAPT. 
The MTA is a functional assay that is significantly different from VerifyNow and GTT that 
show poor correlation to the MTA or clinical antiplatelet effectiveness. The results further 
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demonstrate that citrate may be a poor choice for preserving specimens for later testing of 
high shear thrombosis. Heparin can maintain liquid whole blood with minimal effects on 
SIPA. Future larger-scale clinical studies may demonstrate the MTA’s ability to predict 
MACE in a patient population. 
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CHAPTER 4. ANTITHROMBOTIC THERAPY BY CHARGED 
NANOPARTICLES 
Results detailed in this chapter regarding CNP in porcine whole blood have been reported 
in BioMicrofluidics [76]. 
Abstract 
 Platelet accumulation under high shear rates at the site of atherosclerotic plaque 
rupture leads to myocardial infarction and stroke. Current antiplatelet therapies remain 
ineffective for a large percentage of the population, while presenting significant risks for 
bleeding. We explore a novel way to inhibit arterial thrombus formation.  Theoretically, a 
negative charge may influence the tertiary structure of vWF to favor the globular 
configuration by biophysical means without the use of platelet inactivating drugs. We 
tested this hypothesis experimentally for negatively charged nanoparticles (CNP) to inhibit 
arterial thrombus formation in a microfluidic thrombosis assay (MTA).  Several different 
CNPs demonstrated the ability to inhibit or retard thrombotic occlusion in a laboratory 
microfluidics model that has been validated by clinical arterial thrombosis testing. Our 
hypothesis that particle charge and size matter for antithrombotic CNP is proven.  Further, 
the effect is present with particles of widely varying base compositions, indicating that 
biochemical effects are not dominant.  A preliminary study of safety in mice shows that 
bleeding times are not markedly prolonged. The CNPs tested here show promise as a new 




4.1.1 Current antithrombotic methods 
The main target of current antithrombotic therapies for high shear thrombosis is 
platelet activation. Therapies utilized for this end have been termed more specifically 
antiplatelet drugs. The most commonly utilized antiplatelet is aspirin, which is prescribed 
nearly universally by cardiologists [18, 97]. Aspirin may act as an antiplatelet agent by 
irreversibly inhibiting cyclooxygenase-1 (COX-1) function, thereby interrupting 
thromboxane (TXA2) action that normally induces platelet aggregates [81]. However, 
confidence in aspirin as an antiplatelet agent has greatly diminished with the recent clinical 
results in the ASPREE (randomized and blinded; n = 19,114) and ARRIVE (randomized 
and double blinded; n = 12,546) trials [18-21]. The primary endpoint of each trial was the 
occurrence of cardiovascular death, myocardial infarction, unstable angina, stroke, or 
transient ischemic attack. The outcomes of myocardial infarction, stroke, and ischemic 
attack all result from thrombotic events. Both trials indicated no significant difference in 
the occurrence of major adverse cardiovascular events (MACE) between individuals taking 
aspirin or placebo treatment. The ASPREE trial showed that death related to cardiovascular 
disease was comparable between aspirin (1.0%) and placebo (1.2%) groups [19, 20]. The 
ARRIVE trial showed that the occurrence of MACE was similar between both aspirin 
(4.3%) and placebo (4.5%) groups, as well.  
The same trials also showed a significant increase in the incidence of major 
bleeding associated with aspirin use. The ASPREE trial explored bleeding safety endpoints 
of major hemorrhagic bleeding, with an incidence of 8.6 events per 1000 person years in 
the aspirin group and 6.2 events per 1000 person years in the placebo group (p < 0.001) 
[20]. Meanwhile, the ARRIVE trial investigated rates of intestinal bleeding, with 0.97% of 
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patients on aspirin experiencing gastrointestinal bleeding complications compared to 
0.46% of individuals in the placebo group (p < 0.001) [21]. Therefore, aspirin is likely 
doing more harm than good in most patients, leading clinicians to start recommending to 
discontinue aspirin use [18].  
Other clinically used therapies, such as clopidogrel, abciximab, eptifibatide, and 
PAR-1 antagonists (vorapaxar and atopaxar), aim to inhibit platelet activation and 
interaction with proteins such as vWF and thrombin (Figure 4-1) [24, 25, 86, 98, 99]. 
However, multiple studies found that these drugs do not reduce the rates of mortality in 
patients [98, 99]. Specifically, clopidogrel was investigated similarly to aspirin in the 
“clopidogrel versus aspirin in patients at risk of ischemic events” (CAPRIE) and 
“Clopidogrel and metoprolol in myocardial infarction trial” (COMMIT) trials [100, 101]. 
The CAPRIE study is a blinded, randomized trial of 19,185 patients taking either aspirin 
or DAPT. The rate of MACE in patients taking aspirin alone was 5.83%, which was 
significantly reduced to 5.32% in individuals taking DAPT (p = 0.043) [100]. The 
COMMIT trial investigated clopidogrel against placebo in a blinded, randomized study of 
45,852 patients. Clopidogrel was found to significantly reduce MACE occurrence from 
10.1% in the placebo group to 9.2% in the clopidogrel group (p < 0.01) [101]. While both 
studies found statistical significance between groups, the reduction in MACE rates was a 
fraction of either the aspirin or placebo group. Both studies show that over 90% of 
individuals that would experience MACE in the non-clopidogrel group will still experience 
MACE when adding clopidogrel therapy. Therefore, from a clinical perspective current 
therapies are not significantly pushing the needle, and more effective therapies are still 
needed. 
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Prior to undertaking these large clinical studies (ASPREE, ARRIVE, CAPRIE, and 
COMMIT) that take several years to complete (5-9 years) and large amounts of funding, 
preclinical investigations are required. Per the FDA approval report, the preclinical 
investigations for safety and efficacy of clopidogrel made use of several animal models: 
mice, rats, guinea pigs, baboons, and dogs. However, the scientific community has placed 
an emphasis on finding methodologies that can reduce, refine, or replace the animals used 
in preclinical research [102]. Therefore, in vitro assessments for drugs and therapies are 
being developed to replace animals for a large percentage of preliminary assessments 
[102]. By leveraging these in vitro technologies as high throughput screening systems, 
significant reductions in drug development costs can be achieved and faster 




Figure 4-1. Depiction of antiplatelet mechanisms of action for irreversible 
inactivation (Aspirin and Clopidogrel) or protein receptor inhibition that aim to 
prevent platelet adhesion events to proteins (Abciximab and PAR-1 antagonists). 
4.1.2 Issues with targeting platelet activation 
Currently utilized therapeutic methods for targeting platelet activation have serious 
drawbacks. In some instances, the drug is not able to be metabolized properly due to the 
individual lacking the necessary enzyme, such as the CYP2C19 gene for metabolism of 
clopidogrel [104, 105]. Further, bleeding complications arise due to the irreversible 
inactivation of platelets, leading to platelets circulating in a dummy-like state unable to 
activate in normal hemostatic processes [20, 87]. These side effects/safety issues will 
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continue to arise if antiplatelet therapies are continually designed to act through irreversible 
biochemical inhibition. Therefore, a fundamentally new approach may prove superior in 
the prevention of arterial thrombosis. 
4.1.3 Nanoparticles for biophysical interactions 
There are several requirements for arterial platelet thrombosis, including vWF 
unfolding under high shear, vWF adhesion to a collagen surface, activation-independent 
platelet adhesion to vWF, and platelet activation leading to rapid platelet accumulation. 
While a majority of current therapies target the latter, interfering with any of these stages 
in the process would prevent or inhibit the formation of an arterial thrombus. The initial 
stage of high shear platelet thrombus formation is vWF unfolding under flow and is 
therefore an interesting candidate target that warrants investigation. Preventing vWF 
unfolding under flow, thereby maintaining its globular state, would limit the amount of 
vWF binding to collagen. This in turn could inhibit the subsequent stages of arterial platelet 
thrombosis, without altering internal mechanisms of platelet activation that are necessary 
for healthy hemostatic processes.  
Such interactions may include electrostatic protein interactions with biomaterials, 
thereby changing protein conformations temporarily while that interaction persists [106-
108]. Nanoparticles present a feasible option to promote these protein-biomaterial 
interactions, as it is well known that a plasma protein corona forms around the surface of 
the nanoparticle after entering the blood stream [109]. If multiple nanoparticle materials 
effectively inhibit thrombotic formation, it would be indicative of a mechanism that is not 
dependent on individual material biochemical interactions with blood components. Rather, 
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interactions would be more likely due to general physical characteristics of the 
nanoparticle, such as size and charge. 
4.1.4 Nanoparticles for biomedical applications 
Three nanoparticle materials that have been commonly utilized in biomedical 
applications are polystyrene, PLGA, and gold. Polystyrene (PS) is a biocompatible material 
that is not biodegradable. This material has been utilized in nanoparticle applications of 
biosensors, photonics, and self-assembled nanostructures [110, 111]. It is considered an 
easy material to work with and sterilize for biomedical applications; therefore, it is often 
used as a model material for nanoparticle investigations. 
Poly(lactide-co-glycolide) (PLGA) is an attractive material for nanotherapeutic 
applications as it combines favorable properties of biocompatibility and biodegradability 
[112-116]. Further, PLGA particles carry a distinct advantage as they have already been 
approved by the FDA as vehicles for drug delivery [117]. PLGA has been utilized 
extensively in drug delivery applications because of its biodegradation allowing for 
sustained release of the drug of interest [118, 119]. The degradation takes the form of 
PLGA hydrolytically breaking down to lactic and glycolic acid that are, in turn, 
metabolized via the Krebs’ cycle and eliminated as carbon dioxide and water [117, 120]. 
Therefore, PLGA has been utilized extensively in biomedical applications such as 
vaccination and treatment of cancer, inflammatory diseases, or cerebral diseases [118]. 
However, PLGA nanoparticles for biophysical interactions have not been explored and 
thus present a new therapeutic option by which PLGA based particles may be utilized. 
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Finally, gold has also been utilized in bioacoustics, DNA sensors, and 
bioconjugation for drug delivery applications [121]. It is an attractive material for 
biological applications of nanoparticles due to its stability and biocompatibility. Gold 
nanoparticles are also very easy to synthesize and conjugate with other biomolecules, 
making them adaptable to many biological applications [122]. Like PS and PLGA 
nanoparticles, gold nanoparticles have few to no applications in biophysical applications 
and therapeutics, therefore there are unexplored applications for this base material. 
Nanoparticles in systemic circulation.  
One of the difficulties with utilizing nanoparticles in vivo is that they are rapidly 
cleared from the blood stream via opsonization by the mononuclear phagocyte system 
(MPS). This drastically decreases the efficacy of particles if the target is anything other 
than the mononuclear phagocyte system (MPS). Additionally, for biostable materials such 
as PS and gold, this creates issues of liver and spleen toxicity over time as these organs 
cannot break down the material. Therefore, targeted renal clearance is required for such 
particles. Surface modifications to a polystyrene and gold nanoparticles with thiol mediated 
binding of a polymer such as PEG have been utilized previously to decrease biodistribution 
to the liver and spleen to alleviate this issue [123]. 
The reason for the rapid clearance of PLGA particles from the systemic circulation 
is due to the hydrophobic nature of the PLGA [118]. This has been alleviated in part due 
to advancements in surface coatings of the PLGA base material. Two general methods have 
shown a significant increase in circulation time. One is through the use of a PLGA-PEG 
block co-polymer [120, 124, 125]. Through an oil/water (o/w) emulsion synthesis with 
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PLGA-PEG block co-polymer, particles with a PLGA base and PEG surface may be 
fabricated. While these particles have shown significant increases in circulation time, they 
are termed “stealth particles” due to PEG coatings having decreased interactions with 
biomolecules and proteins [125]. Another method for increasing circulation time is through 
nanoprecipitation synthesis of PLGA with a PVA surfactant [126]. Excess PVA in the 
aqueous phase of the synthesis process interacts with the PLGA particle surface and 
remains there as a stabilizer. The resulting particle has increased hydrophilicity due to the 
PVA coating, therefore increasing the circulation time of the particle. Higher PVA 
concentrations and molecular weights enhance this effect. Therefore, simple modifications 
to the synthesis process may increase particle circulation time. 
Tuning the size of nanoparticles.  
Selection of a suitable nanofabrication method is critical to achieve desired sizes 
during synthesis. Polystyrene nanoparticles are most often fabricated by emulsion 
polymerization, with sizes being altered by changing the polymeric concentration in 
solution and temperature [127]. The three most common methods for polymeric 
nanoparticle synthesis are double emulsion, nanoprecipitation, and spray drying. Double 
emulsion and spray drying techniques typically lead to the production of larger PLGA 
nanoparticles greater than 200 nm [126, 128]. Nanoprecipitation allows for greater size 
control at lower diameters by altering the polymer concentration and synthesis temperature 
[126]. By increasing the batching temperature of the aqueous phase close to boiling and 
decreasing the PLGA concentration in the organic phase, particles smaller than 100 nm 
may be fabricated, while larger particles are fabricated through the reverse properties. 
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Nanoprecipitation, therefore, presents an easy to use methodology for fabricating PLGA 
particle sizes in the 50 to 200 nm range. 
Fabrication of gold nanoparticles is typically done through reduction of gold ions 
with sodium citrate in aqueous solution. By tuning the ratio of gold to citrate ions, the size 
of the particle can be controlled. More citrate ions leads to more rapid and stronger 
stabilization of the gold in solution, creating smaller gold nanoparticles, and vice versa 
[129]. Additionally, the size of the particles can be altered by batching temperature, with 
increases in temperature leading to smaller particle formulations [129]. Sizes can be tuned 
in the 1 to 100 nm range [130, 131]. 
The effects of nanoparticle charge.  
The surface charge, or zeta potential, also carries a significant role in the design of 
nanoparticles for biomedical applications. Several studies have shown that positively 
charged nanoparticles are opsonized more rapidly than negatively charged particles, likely 
due to the net negative charge of amino acid residues on the surfaces of circulating cells 
[119, 132]. Positively charged PS nanoparticles were found to enhance platelet aggregation 
over neutrally and negatively charged particles [106]. Further, positively charged PLGA 
particles induced an increased cytotoxic effect, while negatively and neutrally charged 
PLGA particles had no such effect [132]. The surface charge can be altered through the use 
of different surfactants or surface modifications to the nanoparticle base material [133]. 
Surfactants such as PVA create negatively charged surfaces. More neutrally charged 
particles may be achieved through PEG surface modification, which can then be 
subsequently altered by capping the PEG with different end groups. 
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4.1.5 Objectives and hypothesis 
In order to study the effects of charged nanoparticles on thrombotic inhibition, we 
employed two thrombosis models: the microfluidic thrombosis assay (MTA) for in vitro 
screening and a murine carotid stenosis in vivo model. The MTA was utilized to screen for 
the effects of nanoparticle size, surface charge, and blood concentration with easy to use 
polystyrene particles. From the MTA, we will be able to identify the most effective 
nanoparticle parameters in order to translate into a biocompatible nanoparticle synthesis 
scheme that will also be assessed with the MTA. The most effective particle will also be 
further characterized in the in vivo murine tail bleeding model. I hypothesize that a 
nanoparticle on the same order of size of a vWF monomeric unit (50-60 nm) and matching 
negative charge (~ -50 mV) will provide a strong and repeatable antithrombotic response. 
4.2 Preliminary CFD Results 
Collaboration with Dr. Cyrus Aidun’s research group for computational fluid 
dynamics analysis aided in the design and development of the experimental hypotheses and 
methods [76, 134]. The supporting computational methods and results are reported in this 
section. 
4.2.1 Computational Methods 
 We developed and validated the application of the lattice-Boltzmann (LB) method 
for direct numerical simulation (DNS) of dense suspension of particles in viscous flow 
[135-138], deformable capsules [139, 140], and cellular blood flow [141]. A multiscale 
computation approach has been developed where the CNP and vWF are modeled with a 
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Langevin dynamics (LD) approach fully integrated and coupled with the LB method (LB-
LD) [134, 142]. The vWF is modeled as a chain of N beads (each representing a dimer) as 
done in many previous studies [143-147]. The total force on the particle or bead in LD 
consists of hydrodynamic, Brownian and non-hydrodynamic forces which include any 
external body forces, such as the Lennard-Jones (LJ) potential (employed for attraction 
force between monomers) and electrostatic forces. The electrostatic force is modeled by a 
Coulomb potential as an effective pair potential that describes the interaction between two 
point-charges. The connectivity force between neighboring vWF monomers is modeled 
through a finitely extensible nonlinear elastic (FENE) spring potential, Us [146, 148]. The 
same LD approach is applied to charged nanoscale particles with Us = 0. The LD method 
for modeling the vWF and CNP has been extensively validated including modeling the 
vWF transition from globular to elongated phase at the critical shear rate [13, 134, 142, 
145, 146]. 
 Electrostatic interactions with vWF are induced because of large patches of positive 
charge at the A1 interface. Although the electrostatic charge is not constant, it can be 
estimated to be about on average 6 to 10 kT/e (150 to 250 mV) [149]. In our simulations, 
we take an average of +8 kT/e for the A1 domain implemented as a point charge in each 
dimer.  Modeling the charge of the A1 domain as a point particle in each dimer is an 
assumption that requires further experimental verification.  The average charge of CNP for 
the simulations is -50 mV [150]. 
4.2.2 Computational Results 
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 The conformational dynamics and motion of vWF proteins were simulated using 
the LB-LD method outlined above. The natural vWF exhibits periodic stretching, tumbling 
and folding events under linear shear flow (Figure 4-2A). Without the CNP, the vWF re-
elongates frequently, going through periodic cycles of stretching and relaxation. The 
patterns of elongation in Figure 4-2A are representative of the elongation and folding 
model described previously in Schneider et al [13]. These patterns form independently of 
initial conditions. 
 
Figure 4-2. (A) vWF (blue) without CNP in shear flow (6500 s-1) with arrows 
indicating flow direction. vWF undergoes dynamic elongation and folding, but does 
not remain in a stable globular shape under high shear as indicated by the two 
screenshots above. (B) vWF (blue) immersed in experimental concentrations of CNP 
(red) in shear flow (6500 s-1) with arrows indicating flow direction. vWF polymers 
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fold back into globular form (dense balls) after interaction with CNP, and remain in 
the globular conformation under the same shear rate [76]. 
 
Electrostatic attraction by charged particles was introduced to counteract the 
elongation of vWF from drag forces of high shear stress. The vWF-CNP interaction 
simulations demonstrate that CNP have a demonstrable effect on conformation of vWF 
under shear flow conditions. In the simulation, there are 20 CNP and 10 vWF proteins each 
consisting of 50 dimers. A ratio of two CNPs available per vWF filament was chosen to 
match the relative CNP:vWF concentration used in experiments. The addition of negatively 
charged CNP radically altered the behavior of the vWF in high shear flows.   
Figure 4-2B illustrates the interaction of CNP (red) and vWF (blue) in a constant 
shear flow of 6500 s-1. The elongated vWF wraps the charged CNP into the interior of the 
coiled form, stabilizing this conformation. When the simulation reaches dynamic 
equilibrium, each coiled vWF (6 out of 10 in the bottom snapshot, 2 strands have self-
associated) contains one or more CNP. The vWF-CNP compound maintains the globular 
conformation and does not elongate again at this shear rate. The vWF-CNP effective 
length, i.e. the projected length in flow direction, drops by more than 2/3 to less than 30% 
of its maximum length, suggesting a significant drop in capture power of vWF or a 
lengthening of occlusion time when CNP are mixed in blood. The failure of vWF-CNP to 
elongate would be expected to severely reduce the ability of vWF to capture platelets under 
high shear rate conditions.   
The computational simulation was then used to assess the importance of charge 
sign. The model predicts that CNP with a neutral or positive charge would not hinder the 
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elongation of vWF nor would it induce a preferred globular form of vWF. Only the 
negatively charged nanoparticle is predicted to have an effect on vWF elongation and, 
subsequently, less thrombosis. 
 
4.3 Experimental Methods 
4.3.1 Materials 
 Polydimethylsiloxane (PDMS) was from Krayden, Inc. (Denver, CO, USA). Type 
I collagen was from Chrono-Log (Havertown, PA, USA). Resomer 50:50 (PLGA) was 
purchased from Sigma Aldrich (St. Louis, MO, USA). Polyvinyl alcohol was purchased 
from Sigma Aldrich (St. Louis, MO, USA). PEG-thiols with either carboxyl or methyl end 
groups were purchased from Sigma Aldrich (St. Louis, MO, USA). HAuCl4 was purchased 
from Sigma Aldrich (St. Louis, MO, USA). Calcein AM was purchased from BD 
Biosciences (San Jose, CA, USA). Unfractionated sodium heparin was purchased Fisher 
Scientific (Hampton, NH, USA). 
Testing of the microfluidic thrombosis assay (MTA) was performed on a Leica 
DM6000B microscope from Leica Microsystems, Inc. (Buffalo Grove, IL, USA), along 
with Scout SPX222 balances from OHAUS Corporation (Parsippany, NJ, USA) for mass 
flow rate detection and a high-resolution CCD PixelFly camera from PCO (Kelheim, 
Germany) for image acquisition.  
4.3.2 Nanoparticle synthesis and characterization 
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 Polystyrene, poly lactic-co-glycolic acid, and gold nanoparticles were utilized in 
this study. 50-60 nm and 200 nm polystyrene particles with no modification (PS-CNP) or 
carboxyl surface modification (PSC-CNP) were purchased at a concentration of 10 mg/mL 
from either Bangs Laboratories (Fishers, IN, USA) or Phosphorex, Inc. (Hopkinton, MA, 
USA). Both PLGA and gold nanoparticles were synthesized in house by the methods below 
(Figure 4-3). 
PLGA Nanoparticles. Biodegradable PLGA-CNP were fabricated in house by 
nanoprecipitation, similar to previously published methods [132]. 100 mg of RG503H 
Resomer® (Sigma Aldrich) was dissolved in acetone. The dissolution was performed over 
5 minutes at 150 g stirring. Ultrapure water was added with continued stirring at 150 g for 
3 hours to create a final PLGA-CNP concentration of 10 mg/mL. PLGA-PVA particles 
were also fabricated by addition of a 5% PVA (~20,000 MW) solution rather than ultrapure 
water. Particles on the order of 50 nm were synthesized at 90°C, while particles on the 
order of 150 nm were synthesized at room temperature (~25°C). Particles were washed by 
microcentrifuge at 4,500 x g for 20 minutes. 
Gold Nanoparticles. Gold nanoparticles modified with Poly (ethylene glycol) 
carboxyl thiol (PEG-C) and PEG-methyl ether thiol (PEG-M) were utilized in this study. 
PEG-Carboxyl thiol (7500 Mn) and PEG-methyl ether thiol (6000 Mn) were purchased 
from a supplier (Sigma Aldrich). 1 mM bulk solutions of each substance were created using 
deionized water. The PEG solutions were then stored in a freezer at -20˚C prior to use. 
Spherical citrate capped gold nanoparticles were synthesized as described by Manson et al 
and Wang et al [151, 152]. Deionized water (198 mL) and 25 mM gold(III) chloride 
trihydrate (HAuCl4•3H20, 8 mL) was boiled and refluxed in a 250 mL flat-bottom beaker 
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on a temperature-controlled hot plate with continuous stirring. Sodium citrate solution (18 
mL of 20 mM solution) was added to the boiling chloroauric acid solution, removed from 
heat and left to stir for 20 minutes to ensure completion of the reaction. Varying 
concentrations of PEG-C and PEG-M were added to the citrate capped nanoparticles in 
order to create 100 mL solutions of PEG-capped AuNPs. After thawing and agitating each 
of the 1 mM PEG solutions, the following PEGylated nanoparticle solutions were created: 
PEG-AuNP-C (141 µL of PEG-C solution) and PEG-AuNP-M (141 µL of PEG-M 
solution). Each solution was left to rapidly stir overnight at room temperature to complete 
the exchange of citrate molecules and PEG. The PEGylated AuNP solutions were then 
washed by microcentrifuge at 4,500 x g for 20 minutes. The supernatant was removed, 
leaving the AuNP pellet at the bottom of each centrifuge tube. The pellet was washed by 
adding 100 µL of phosphate-buffered saline (PBS) to each tube, agitated and re-spun in the 
centrifuge using the same settings. This process was repeated to remove excess PEG and 
other reactants [151]. This process, which takes several hours across two days, yielded 
approximately 3 mL of gold nanoparticles at a concentration of 2.0 x 1013 CNP/mL. 
Additionally, the use of PEG in the gold nanoparticle formulation substantially increases 
the batching cost from ~$0.19/mL for citrate stabilized gold CNP to ~$2.77/mL for PEG 
stabilized gold CNP, representing a 1458% increase in price. 
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Figure 4-3. Synthesis protocol for (A) PLGA and (B) gold CNP. Polystyrene particles 
utilized in the study were purchased from either Bangs Laboratories or Phosphorex, 
Inc. [76] 
 All particles (PS, PLGA, and gold) were stored at 4° C until needed for 
characterization or blood treatment. Prior to use, the CNP were vortexed for 10 seconds to 
evenly disperse and minimize agglomeration. Characterization of average diameter and 
zeta potential was performed by addition of 100 µL of the 10 mg/mL CNP mixture to 900 
µL of deionized water for a final test concentration of 1 mg/mL. Diameter was measured 
by dynamic light scattering, while zeta potential was measured by photon correlation 
spectroscopy (ZetaSizer Nano-ZA, Malvern Instruments). 
4.3.3 Blood collection 
 Porcine. Porcine whole blood was obtained from a local abattoir (Holifield Farms, 
Covington, GA) and lightly heparinized at 3.5 USP units/mL, as previously described by 
Para et al [77]. Blood was stored at room temperature on a rocker prior to testing. All 
testing was completed within 8 hours after collection. 
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Human. Healthy volunteers were older than 18 years of age and had no prior history 
of cardiovascular disease and no antiplatelet medication in the 10-days prior to enrollment. 
Individuals with known anemia (hematocrit < 30%) or transmittable blood diseases were 
excluded. The MTA was the only PFT utilized in this proof-of-concept study. All subjects 
were recruited in accordance with the Institutional Review Board of the Georgia Institute 
of Technology (IRB #17315). 
4.3.4 Blood treatment with CNP 
 Blood samples were treated with varying concentrations of CNP immediately 
before the flow assay. Estimations of the appropriate dose were based on average plasma 
vWF molecule concentrations. An approximate vWF concentration was calculated at 1.4 x 
1011 molecules/mL of blood, assuming a mass concentration of 5 µg/mL and average length 
of 4µm for plasma vWF. Values were converted to a stoichiometric CNP:vWF ratio, given 
the relative CNP dose to the approximated amount of vWF molecules in a whole blood 
sample. Concentrations of CNP investigated in this study ranged from 0.5 to 10 CNP:vWF. 
Stoichiometric concentrations of PLGA-CNP and AuNP-CNP were selected based on 
results of the PS-CNP investigation. 
4.3.5 In vitro microfluidic thrombosis assay (MTA) 
The microfluidic channels were fabricated by gray-scale lithography techniques 
previously described [48]. Fibrillar type I collagen-coated (100 µg/mL)  microfluidic chips 
are positioned on the stage of a light microscope with a 4X objective and connected to an 
upstream reservoir with Tygon tubing, similar to previously described [3]. Downstream 
tubing leads to a discharge reservoir placed on a precision balance to measure mass flow 
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rates. Images of thrombus formation are acquired at 1 Hz with a high-resolution CCD 
camera. Image acquisition is facilitated by the µManager open-source microscopy software 
[78]. Occlusion time (OT) is measured as the time from first blood contact with the stenosis 
to the time of the initial maximum mass balance reading. Image and flow-rate post-
processing was performed with custom code (MATLAB, MathWorks). 
4.3.6 Platelet surface coverage analysis 
An assessment of platelet surface coverage in the microfluidic was also performed 
to determine the effects of CNPs on overall platelet adhesion. The MTA was utilized again 
for this assessment, was fixated on the stage of a fluorescent microscope (AxioObserver, 
Zeiss). Human whole blood samples were treated with optimal nanoparticle doses, as 
determined in the OT assessment described previously. Immediately prior to testing the 
blood samples in the MTA, Calcein AM was added to the blood sample at a concentration 
of 1.0 µM (BD Biosciences). Samples were processed in the MTA per the methods 
described above. Fluorescent images were collected and processed with MATLAB 
counting the number of pixels with fluorescence, indicating platelet surface coverage. 
4.3.7 In vivo murine tail bleeding model 
Although the microfluidic device mimics the in vivo atherosclerotic environment, 
it does not allow for an assessment of bleeding risk; therefore, it is necessary to perform in 
vivo hemostatic safety experiments. A tail-bleeding model was utilized to determine the 
effect of each agent on normal hemostasis. Animals were anesthetized with a 
ketamine/xylazine cocktail injection (87.5 mg/kg ketamine, 12.5 mg/kg xylazine, 0.1 mL 
cocktail / 20g mouse weight). Ten (10) wild-type (C57B1/6) mice were separated into two 
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groups (n = 5 per group): CNP (n=5) or PBS placebo (n=5) was injected into the tail vein 
of the mouse. The number of animals was selected based on sample sizes utilized in similar 
tail-bleeding assessments of  a previous study [153]. This was followed by cleanly cutting 
1 cm off from the tip of the tail and submerging the injured tail into a vial of saline. The 
bleeding from the tail was timed until blood ceased to flow into the saline vial, indicating 
hemostasis at the site of injury. 
4.3.8 In vivo murine carotid thrombosis model 
In order to study in vivo efficacy, a relevant animal model of thrombosis must be 
selected. The murine ferric chloride thrombosis model is a popular choice in this field [154, 
155]. However, recent reports have indicated that the chemical-induced injury leads to 
abnormal clot formation [156]. Therefore, an arterial physically-induced injury model was 
utilized in this study through the modified-Folts model, which creates a high shear 
environment [153]. 
Ten (10) wild-type (C57B1/6) mice were separated into two groups (n = 5 per 
group): CNP treated and negative control non-injury. The number of animals was selected 
based on statistically significant results found in a previous study using similar sample 
sizes in the modified-Folts model [153]. Animals were anesthetized with the same protocol 
as above. Mice were placed on their back with a midline incision performed on the neck to 
isolate the right common carotid artery. A flow probe connected to a blood flowmeter was 
gently placed around the isolated artery. Silk suture was lightly tied distal to the flow probe 
and continually tightened until flow has decreased by 50%. Prior to inducing injury, CNP 
or PBS placebo injection was performed via intravenous bolus through the tail vein. 
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Arterial injury was induced by crushing the artery with artery forceps directly over the 
suture [153]. Flow rates were monitored over the course of the 60-minute experiment to 
monitor the development of occlusive thrombi and vessel perfusion. After 60 minutes, the 
animals were euthanized by cervical dislocation. 
4.3.9 Statistical methods 
 All data is presented as the average and standard deviation, unless otherwise 
specified. A student’s t-test was used to determine statistical differences between 
experimental groups and control values at the same concentrations for both in vitro and in 
vivo data [77]. 
4.4 Results 
4.4.1 Effects of PS CNP Charge on Porcine In Vitro Thrombosis 
 In an initial screen of the effects of CNP on porcine whole blood thrombosis, three 
different surface modifications of 60 nm polystyrene were assessed: carboxyl, amine, and 
non-treated. These modifications represented negative, positive, and neutral charges of 
CNP, respectively (Table 4-1). Doses of nanoparticles were varied between 1.2-12 x 1011 
nanoparticles/mL of blood, which corresponds to estimated ratios of 1:1 to 10:1 CNP to 
vWF molecules in whole blood samples. Porcine blood samples (n = 4) were subjected to 
a high shear rate environment of 10,000 s-1 with a fibrillar collagen surface in the MTA. 
Images acquired during the duration of the experiment made it possible to qualitatively 
determine the level of platelet accumulation and observe thrombus formation (Figure 4-4). 
The amount and rate of thrombus formation was comparable for both control and PS-CNP 
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conditions. However, significant differences in the amount of light transmitted between the 
control and PSC-CNP (60 nm) groups were found at time points of 90, 120, and 180 
seconds (Figure 4-5). The control group (saline addition) occluded quickly (tocc = 133 
seconds).  In contrast, the PSC-CNP treated group remained in the initial platelet adhesion 
phase (lag phase), with accumulation occurring at a much slower rate than normal. 
Although the images of PSA-CNP might indicate that they were also effective in inhibiting 
thrombus formation, video evidence from all samples treated with PSA-CNP showed large 
platelet emboli passing through the channel, occasionally getting stuck in the stenotic 
region or upstream. Therefore, PSA-CNP were eliminated from further assessment as they 
induced platelet aggregation. 
 
Figure 4-4. Experimental results comparing the control (untreated) whole blood 
condition and the addition of 60 nm polystyrene (PS), polystyrene-carboxyl (PSC), 
and polystyrene-amine (PSA) nanoparticles at a concentration of 1.8 x 1011 
nanoparticles/mL. Flow is from left to right in each image. The comparison indicates 
similar thrombotic events in control and PS, while thrombus formation is delayed in 
PSC. Although hard to see in the still frames, samples treated with PSA had several 
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microthrombi form and pass through the channel, sometimes lodging in the upstream 
portion, which caused channel occlusion rather than thrombus formation on the 
collagen coated surface. 
 
 
Figure 4-5. The PSC-CNP significantly retarded thrombus formation as quantified 
by light transmittance (1.8 x 1011 nanoparticles/mL). The overall light transmittance 
in the channels was found to be significantly different between the control and PSC-
CNP at times of 90, 120, and 180 seconds (*p-value < 0.01, n = 4; error bars represent 
standard deviation). 
 
PSC CNP delayed occlusion time up to 4X 
Across the dosing scheme of 1.2-12 x 1011 nanoparticles/mL, the 60 nm PSC-CNP 
were found to have a narrow efficacy range in their ability to inhibit thrombus. The peak 
concentration was found to be around 2.0 x 1011 particles per mL of blood and with an 
approximately 4-fold increase in occlusion time compared to the control group (Figure 
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4-6A-B). However, the effect of the PSC-CNP began to diminish as the concentration was 
increased beyond this range.   
 
 
Figure 4-6. Occlusion time dose response of both PSC 60nm CNP and PLGA CNP in 
the arterial thrombosis microfluidic assay. (A) 60 nm PSC-CNP had a narrow dose 
response, with a maximum effective concentration between that led to an 
approximate 4X increase in OT (B). (C) PLGA-CNP had a peak at a similar 
concentration to that of the PSC-CNP, but led to an approximate 12X extension in 
OT (D). Statistical significance was determined from treated group compared to the 




4.4.2 Effects of PLGA CNP on Porcine In Vitro Thrombosis 
 Next, we investigated whether this effect was also observed with another negatively 
charged particle. PLGA-CNP were synthesized at room temperature using 
nanoprecipitation methods and were found to have a size of 155nm and zeta potential of -
32.1 mV (Table 4-1).  The concentrations of PLGA-CNP tested in the arterial thrombosis 
assay was then varied around the peak observed with the 60 nm PSC-CNP, with eight 
calculated ratios between 1.0-10 x 1011 particles per mL of blood. 
 The results of the MTA with porcine whole blood indicated a similar peak in this 
range of CNP concentrations, with a maximum effective concentration found at 
approximately 2.0 x 1011 PLGA-CNP per mL of blood (Figure 4-6). At this concentration, 
the occlusion time was delayed by an even greater 12-fold from the control case. This effect 
also diminishes to nearly baseline occlusion times at concentrations outside the optimal 
ratio, similar to the 60 nm PSC-CNP.  
Nanoparticle Characterization from in vitro porcine experiments 
 PS-, PSC-, PSA-, and PLGA-CNP characterization of hydrodynamic diameter 
(DCNP) and zeta potential (ZPCNP) were determined with the use of a ZetaSizer instrument 
(ZetaSizer Nano-ZA, Malvern Instruments; Table 4-1). The purchased polystyrene 




Table 4-1. Quantified characteristics of CNP utilized in the porcine whole blood 
testing. 
 DCNP (nm) ZPCNP (mV) 
PS-CNP 65.0 -6.1 
PSC-CNP 80.0 -48.0 
PSA-CNP 62.0 +26.0 
PLGA-CNP 155.0 -32.1 
 
4.4.3 Polystyrene CNP parametric analysis in human whole blood 
The high shear MTA was utilized to confirm that the results found previously with 
porcine whole blood translated to human whole blood [76]. Given the hypothetical 
mechanism of CNP and vWF interaction previously proposed [76], a screening experiment 
was designed ranging from an approximate 1:2 to 2:1 CNP to vWF ratio. An approximate 
vWF molecular concentration in blood is 1.4 x 1011 molecules per milliliter of blood, given 
a soluble vWF mass concentration of 5 µg/mL and average length of 4 µm/molecule [157-
159]. Polystyrene nanoparticles of either 50 or 200 nm diameter and carboxyl-
functionalized (PSC50 or PSC200) or non-functionalized (PS50 or PS200) surface were 
investigated in blood collected from five donors with four experimental replicates for each 
donor. All particles were characterized for charge and size prior to testing (Table 4-2). 
PSC50 significantly inhibited thrombosis at three of four concentrations tested, with the 
exception of 1.4 x 1011 particles/mL (Figure 4-7). PS50 significantly inhibited thrombus 
formation only at 1.4 x 1011 particles/mL (Figure 4-7). Neither PSC200 nor PS200 
significantly inhibited thrombus formation at any concentration tested. After normalizing 
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to baseline occlusion times for each sample, PSC50 was found to have a peak effect at a 
concentration of 1.8 x 1011 particles/mL, which was statistically significant to all other 
particle types (Figure 4-7). Inhibition was significantly greater for PSC50 at this 
concentration than all other particle types, which is behaviorally consistent with previous 
results of similarly sized particles in a porcine whole blood model [76]. PSC200 particles 
were found to have a similarly significant impact in only 2 of 5 individuals investigated, 




Figure 4-7. Polystyrene CNP results in the MTA with human whole blood. Average 
occlusion times across the human blood samples for polystyrene-carboxyl (A) and 
native polystyrene (B) CNP (n = 5 samples, 4 experimental replicates per samples). 
Significant differences were calculated for each particle type with respect to the 
baseline value for each particle (*p < 0.01). Occlusion times were normalized to the 
baseline value for each particle type for each particle type (C-D). The peak value of 
PSC50 particles at 1.8 x 1011 particles/mL of blood was found to be statistically 
significant compared to all other particle types at the same concentration (#p < 0.05).  
 
4.4.4 PSC50 CNP inhibit human platelet surface coverage in vitro 
An investigation into the amount of platelet adhesion over time was also performed 
utilizing fluorescent microscopy. The top performing polystyrene particle (PSC50) was 
selected for characterization at its optimal dose of 1.8 x 1011 particles/mL. Adhesion of 
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platelets was delayed, and surface coverage was less dense in the PSC50 CNP group over 
the saline-treated control group (Figure 4-8).  
 
Figure 4-8. Calcein platelet stain comparing the adhesion and accumulation of 
platelets in the stenotic MTA over time for PBS (control) and PSC-50nm conditions 
(flow is from top to bottom). The shaded regions represent the standard deviation of 
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the surface coverage for the average across the assessed channels at each time point 
(N = 4).   
 
4.4.5 PLGA CNP inhibits thrombosis in human whole blood 
In addition to assessing polystyrene CNP in vitro in human whole blood, we aimed 
to assess the effects of other nanoparticle base materials. Unmodified PLGA particles were 
then investigated for their antithrombotic properties in human whole blood in vitro. 
Particles close to 80 nm in diameter were synthesized by nanoprecipitation at 95°C. In 
addition, 150 nm particles were synthesized at room temperature as previous results 
indicated a powerful antithrombotic response of 150 nm PLGA particles in porcine whole 
blood [76]. Smaller PLGA CNP did not have a strong antithrombotic effect (Figure 4-9). 
However, the larger PLGA CNP (150 nm) had a large antithrombotic effect, with a peak 
effect leading to OTs that are 4 times longer (Figure 4-9). However, the unmodified PLGA 
particles have practical limitations for in vivo use, as their hydrophobic nature causes them 
to be rapidly cleared from the blood stream. Therefore, surface modifications to increase 
the hydrophilicity of the PLGA CNP were investigated.  
 PLGA with a PVA surfactant modification was synthesized at both small (~80 nm) 
and large (~150 nm) diameters. Similar effects based on size were observed for both 
surface modifications as with the unmodified PLGA CNP (Figure 4-9). PLGA-PVA 150 
nm had a sustained response across multiple doses to extend OT by approximately three 
times the baseline value. Therefore, the antithrombotic effect of unmodified PLGA is 
preserved after surface modifications to create a more hydrophilic CNP for in vivo 
assessment (Figure 4-9). 
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 The larger PLGA-PVA was then assessed for platelet adhesion and surface 
coverage over time compared to PBS control by fluorescent microscopy (Figure 4-10). 
Full occlusive thrombus was formed by 250s for the PBS control, while significantly less 
adhesion was observed over time in the PLGA-PVA treated condition (Figure 4-11), 
similarly to the previous comparison of PSC50 CNP and PBS (Figure 4-8). The intensity 
analysis indicates that the platelet adhesion plateaus in about twice as much time and with 
significantly less platelet coverage in the channel. 
 
 
Figure 4-9. Other biocompatible CNP formulations of (A) PLGA (n = 4-6) and (B) 
PLGA-PVA (n=4-7) CNP show an effect on occlusion time in the MTA. Each PLGA-
based particle type was investigated at a particle size of approximately 150 nm and 
80 nm. For each type of PLGA-based particle, the larger sized particle led to a 
stronger inhibitory effect on thrombus formation, which was not consistent with the 




Figure 4-10. Calcein platelet stain comparing the adhesion and accumulation of 
platelets in the stenotic MTA over time for PBS (control) and PLGA-PVA CNP 




Figure 4-11. Rates of platelet adhesion (top) and blood mass accumulation from the 
outlet (bottom) during the MTA assessment for both PBS-treated control and PLGA-
PVA CNP treated groups (N = 4). PLGA-PVA CNP treated whole blood led to 
significantly slower and less platelet coverage than the PBS-treated control group, 
which corresponds to the OT’s determined from the mass flow data. Therefore, CNP 
decrease the rates of platelet adhesion, subsequently elongating OT in the MTA. The 
shaded regions represent the standard deviation of the surface coverage for the 
average at each time point across the assessed channels.   
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4.4.6 AuNP loses mild antithrombotic effect with PEG coatings 
After the screening assay for the effects of size and charge indicated that a 50 nm, 
negatively charged particle led to a significant effect on thrombus formation, gold (AuNP) 
was utilized as a base material to fabricate a biostable, biocompatible particle. AuNP 
stabilized by citrate ions was fabricated by reduction of gold ions. This led to particles of 
size 45 nm and -38.0 mV. The AuNP were assessed in the MTA at the same concentrations 
as the polystyrene CNP (Figure 4-12A). A significant effect of citrated AuNP over 
baseline conditions was found at 1.8 x 1011 CNP/mL, but was not to the same level of 
inhibition as the PSC50 CNP. 
The synthesis was also modified to fabricate gold particles that were more 
hydrophilic in nature and would thus have increased circulation times in an in vivo setting. 
Polyethylene-glycol (PEG) was utilized as a surface modification to enhance blood 
circulation time. Two PEGs capped with either a carboxyl (PEGC) or methyl (PEGM) 
group were utilized to create zeta potentials similar to the PSC50 and PS50 CNP, 
respectively ( 
Table 4-3). AuNP-PEGM had a very mild inhibitory effect, similar to the PS50 
particles, in the MTA in human whole blood. However, AuNP-PEGC did not yield similar 
inhibition to the PSC50 particles, with a very similar dosing profile to the AuNP-PEGM 
(Figure 4-12).  
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Figure 4-12. (A) Citrate stabilized gold nanoparticles (AuNP) at ~50nm investigated 
at the same doses as the polystyrene CNP (n = 4). A significant inhibitory effect was 
found at the same dose as PSC50 CNP, although the effect was smaller. (B) More 
neutrally charged AuNP-PEGM (n = 3) mimics the behavior of PS50; however, the 
more negatively charged AuNP-PEGC (n = 3) does not mimic the magnitude of effect 
observed with the PSC50 CNP (*p < 0.05).  
 
4.4.7 CNPs do not affect in vivo hemostasis 
 PSC50 CNP were investigated in a murine tail bleeding model to determine the 
effects of each agent on normal hemostasis (Figure 4-13). In order to counter rapid 
clearance of the PSC50 CNP in vivo within the first few minutes of administration a dose 
of 1.8 x 1013 PSC50 CNP/mL was administered as previous studies suggest approximately 
1% of similar polystyrene-carboxyl particles remain in the blood 1-3 hours after venous 
injection [131, 160, 161]. No significant difference in bleeding time was found between 
CNP and PBS controls, indicating that the CNP does not alter normal hemostatic processes. 
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Figure 4-13. (A) Assessment of PSC50 CNP and PBS placebo in a murine tail bleeding 
model found no difference in tail bleeding times, indicating that CNP do not impact 
hemostatic function. (B) Carotid OTs were determined for both PBS and PSC50 CNP 
treated mice, which found no statistical difference between the two groups. However, 
two of the PSC50 CNP treated mice led to OTs that were approximately 3-4X longer 
than control OTs. (C) Reperfusion of the carotid artery after clot formation did not 
occur in any of the PBS treated mice. However, unstable perfusion leading to other 
clot formations occurred in 2/5 of PSC50 CNP treated mice and stable reperfusions 
with no subsequent clot formation occurred in another 2/5 of CNP treated mice. This 
indicates that CNP have an impact on in vivo clot formation and stability.  
 
4.4.8 CNP’s Impact on In Vivo Thrombus Formation 
PSC50 CNP were investigated in a modified-Folts murine carotid arterial injury 
model and compared to a phosphate buffered saline (PBS) placebo (Figure 4-13). In order 
to counter rapid clearance of the PSC50 CNP in vivo within the first few minutes of 
administration, a dose 100-times greater the optimal dose in vitro was administered as 
previous studies suggest approximately 1% of similar polystyrene-carboxyl particles 
remain in blood 1-3 hours after venous injection [131, 160, 161]. The PBS placebo dose 
led to stable clot formation in an average of 4.7 minutes (N = 5) and no reperfusion of the 
clot was observed during the 60-minute observation period. When dosed with CNP, 
occlusive clots formed in an average of 11.0 minutes (N = 5), which was not statistically 
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different than the control condition. However, 2/5 of the mice developed OTs that were 
approximately 3-4 times longer than the control OTs, indicating that CNP were impacting 
thrombotic activity in those animals. Additionally, 4/5 of the clots in the CNP-treated mice 
led to either stable or unstable reperfusion shortly after. This indicates that the strength of 
the clot was also affected by the CNP. However, a negative side-effect of increased 
respiratory activity was noticed in the mice treated with PSC50 CNP vs. PBS. 
4.4.9 Characterization of CNPs 
Characterization of the hydrodynamic diameter (DH) and zeta potential (ZP) for all 
nanoparticles utilized in this study were performed with Malvern ZetaSizer and Malvern 
NanoSight instruments. The values for each parameter are summarized in Table 4-2, Table 
4-3, and Table 4-4. 
 
Table 4-2. Characterization of purchased polystyrene CNP hydrodynamic diameter 
(DH) and zeta potential (ZP) of the stock solutions. 
 PSC50 PS50 PSC200 PS200 
DH (nm) 53.7 44.9 185.8 189.2 
ZP (mV) -33.8 -12.4 -26.6 -9.4 
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Table 4-3. Characterization of synthesized biostable AuNP CNP hydrodynamic 
diameter (DH) and zeta potential (ZP) of the stock solutions. 
 Au-PEGC Au-PEGM Au-Citrate 
DH (nm) 61.3 40.6 45.7 
ZP (mV) -40.0 -6.7 -37.7 
 
Table 4-4. Characterization of synthesized biodegradable PLGA CNP hydrodynamic 
diameter (DH) and zeta potential (ZP) of the stock solutions. 
 PLGA80 PLGA150 PLGA-PVA80 PLGA-PVA150 
DH (nm) 90.1 146.7 85.6 130.4 
ZP (mV) -33.3 -34.8 -34.3 -32.1 
 
4.5 Discussion 
Prevention of arterial thrombosis has generally been through irreversible 
biochemical targets of platelet activation. In the present study, we present a new approach 
to retard arterial thrombosis by altering the physical tertiary structure of vWF rather than 
destroying platelet activity. Since vWF elongation is necessary for rapid platelet 
aggregation, negatively charged particles may attract positively charged A1 domains into 
 119 
a compact, globular structure that resists elongation by high shear. We find that several 
such negatively charged nanoparticles can retard thrombotic occlusion time in a high 
shear/collagen microfluidics assay. The nanoparticles made of multiple materials with no 
conjugated pharmacological agents demonstrate antithrombotic properties that are more 
effective than aspirin or Plavix. The prolongation in occlusion time is more consistently 
effective over a wide range of samples of whole blood from many porcine and human 
subjects. Additionally, CNP showed to have an effect on carotid thrombus stability in vivo. 
Thus, CNP may be an inexpensive alternative to the effective, but very expensive ReoPro 
[162]. Further, the nanoparticles did not prolong tail bleeding time for mice at high doses 
indicating a margin of safety different from current antiplatelet pharmaceuticals.  
4.5.1 vWF as a target for CNP 
The two major blood components in arterial thrombosis, vWF and platelets, may 
be likely targets for this CNP interaction. vWF appears to be a likely target for this 
interaction, as the approximate stoichiometric ratio between vWF and the effective CNP 
concentration is on the order of 1:1. In silico models from our research group have shown 
that such an electrostatic interaction between CNP and vWF molecules at this ratio can 
possibly alter the folding of the protein to prevent elongation under high shear arterial flow 
[76, 134, 142]. Flow based single-molecule studies of vWF elongational dynamics similar 
to those performed by Fu et al may prove to be useful in elucidating this hypothesis [159]. 
This single-molecule methodology has already been utilized to show that electrostatic 
interactions in high saline concentrations can alter vWF folding under high shear, thus a 
similar mechanistic experiment with CNP may allow for the smart-design of CNP 
parameters to prevent vWF elongation by electrostatics under flow [163]. 
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The CNP demonstrate an unusual therapeutic dose curve with a peak around 2.0 x 
1011 CNP per mL of blood and return to near baseline rather than having the sigmoid dose-
response curve of pharmaceuticals. This peak effect may be due to competing physical 
interactions between plasma proteins. The protein corona significantly changes over time, 
with the corona forming within 30 seconds and specific protein concentrations going from 
low to high and vice versa while incubated in blood [164]. Along with time effects, size 
and material of the nanoparticle play a critical role in plasma protein corona formation 
[109, 165, 166]. Changing the concentration of nanoparticles effectively changes the 
amount of biomaterial surface area, which may in turn impact the protein interactions in 
blood flow. Another potential reason for the decreased effect at higher concentrations may 
be due to electrostatic repulsion between negatively charged nanoparticles as they become 
more concentrated, which may alter interactions with blood components. Multiple 
negatively charged particles on the same vWF molecule may induce repulsive elongation 
rather than attractive compaction. This would create a mountain peak dose-response curve 
instead of the sigmoid curve of saturation.   
4.5.2 CNP efficacy compared to aspirin and DAPT 
The in vitro results of the CNP antithrombotic effect are also promising in the wake 
of the results observed in the previous aim of this thesis characterizing the antithrombotic 
effects of aspirin and Plavix. For this discussion, only results of the MTA with heparin 
anticoagulation will be used for comparison to the CNP, as that was the same anticoagulant 
utilized in this aim. The MTA found an effect of aspirin in in only 2/20 (10%) of healthy 
individuals on week-long therapy, and this effect was mild across the population with the 
average OT increasing by only 1.3 times the pre-aspirin baseline. Looking at the cardiology 
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patients, only 3/20 on aspirin therapy and 3/15 on DAPT had extended OTs. PSC50 
increased the average OT by 3.2 times the baseline value at its optimal dose and extended 
OT by at least 3 times for each of the 5 blood samples tested. PLGA-PVA similarly 
extended OT by approximately 3 times in each of the 7 blood samples tested. And while 
no significant difference was found between PBS and CNP in time to occlusion in vivo, it 
appears that CNP may alter clot stability and strength as reperfusion occurred in 4/5 
animals treated without a significant increase in bleeding time. Therefore, further pre-
clinical development of the nanoparticle therapy and delivery should be investigated and 
directly compared to current antiplatelets. 
4.5.3 CNP effects: human vs. porcine whole blood 
Another interesting finding was the decrease in CNP antithrombotic efficacy in 
human whole blood compared to porcine whole blood. In particular, PLGA-CNP had a 
greater than 10-fold impact on occlusion time in porcine whole blood, while similar doses 
only had a 4-fold impact in human whole blood. Assuming that the mechanism of CNP 
anti-thrombotic effect is electrostatic interaction with vWF, a potential reason for this 
difference between the two species is that the vWF proteins are slightly different [167]. 
Porcine vWF lacks four continuous residues in the GPIb binding site region of the vWF-
A1 domain, and also has additional positively charged residues in its sequence. Therefore, 
vWF-A1 binding with GPIb may be inherently weaker in porcine whole blood, as well as 
enhanced electrostatic interactions with negatively charged nanoparticles due to an 
increase in positive domains of the protein. The combination of these two properties of the 
porcine vWF may explain why there is such a difference in CNP efficacy as compared to 
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human whole blood. We will explore optimization of a wider range of CNP efficacy to 
human blood in the future. 
4.5.4 Limitations and future work 
This work is limited by several shortcomings. First, there are many possible 
nanoparticle formulations based on size, charge, and base material (among other factors) 
that were not assessed in this aim. The assessment with the polystyrene and PLGA 
nanoparticles show that the size alone inhibits thrombus formation differently across 
different base materials. Therefore, each base material should be assessed across a series 
of sizes to determine the optimal size for each material. Delivery and persistence of 
nanoparticles was not addressed as different materials are cleared from circulation by 
different mechanisms. A localized delivery method could be utilized to better control 
dosing and limit systemic metabolism of CNP.  A possible approach might be to utilize 
shear-responsive microparticles detailed by Korin et al [168]. Another limitation is that 
although significant delays in thrombotic formation were observed with CNP use, 
experiments still ended in the ultimate formation of an occlusive thrombus. It is unknown 
whether clinical effectiveness requires complete prevention or only reduction in thrombus 
growth rates to prevent MACE.  Additional uses for CNP could include acute injection 
during MACE to slow down thrombus formation during transport to an emergency facility. 
4.6 Conclusion 
This study effectively demonstrates a new therapeutic for reducing acute arterial 
thrombosis based on preventing the shear elongation of circulating vWF. CNP 
administered into whole blood significantly prolonged occlusion times by up to 12-fold in 
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an arterial-like microfluidic system with high shear rates and collagen that routinely goes 
to thrombotic occlusion. The effect is seen in multiple particles of differing size and charge, 
with a non-sigmoid dose-response curve, illustrating the non-pharmacologic mechanism of 
anti-thrombosis. Further, in vivo murine studies show no significant increase in bleeding 
due to CNP. This study opens the door for further investigation into CNP modifications 
and pre-clinical assessments to increase antithrombotic potential of CNP. Thus, CNP may 
be an inexpensive alternative to the effective, but very expensive ReoPro, without the 
inherent bleeding side-effects. As such, CNP may lead to a new type of antithrombotic 
therapy that acts through biophysical means as opposed to less effective pharmacological 
pathways of inhibiting platelet activation.  
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CHAPTER 5. CONCLUSION 
 
5.1 Original Contributions 
The following peer-reviewed journal articles have been published previously from this 
work: 
1. Griffin MT, Kim DA, Ku DN. “Shear-Induced Platelet Aggregation: 3D-
Grayscale Microfluidics for Repeatable and Localized Occlusive Thrombosis.” 
Biomicrofluidics, 2019. 13(5): 054106. 
2. Griffin MT, Zhu Y, Liu Z, Aidun CK, Ku DN. “Inhibition of High Shear Arterial 
Thrombosis by Charged Nanoparticles.” Biomicrofluidics, 2018. 12(4): 042210. 
3. Zhu Y, Liu Z, Griffin MT, Ku DN, Aidun CK. “Conformational Dynamics of 
Charged Polymers Interacting with Charged Particles.” APS, 2018. 
4. Hastings SM, Griffin MT, Ku DN. “Hemodynamic studies of platelet thrombosis 
using microfluidics.” Platelets, 2017. 28(5): 427-33. 
 
The following patent application is pending: 
 
1. Griffin MT, Aidun CK, Ku DN. “Compositions and Methods for Inhibition Shear 
Induced Platelet Accumulation.” US 2019/0343871 A1. Published 14 November 
2019. 
The following publications are in preparation: 
1. Griffin MT, et al. “Platelet Function Test Comparison of the Microfluidic 
Thrombosis Assay (MTA), GTT, and VerifyNow PRU Test.” 
2. Griffin MT, et al. “Non-Pharmacologic Charged Nanoparticles Inhibit Shear-
Induced Platelet Aggregation.” 
We have presented following peer-reviewed abstracts at major conferences: 
1. Zhu Y, Liu Z, Griffin MT, Ku DN, Aidun CK. “Behavior of Von Willebrand 
Factor (VWF) and Platelet Interaction Under Shear Flow.” 71st Annual Meeting 
of the APS Division of Fluid Dynamics. 11/2018. 
2. Griffin MT, Zhu Y, Liu Z, Aidun CK, Ku DN. “Inhibition of Arterial 
Thrombosis with Charged Nanoparticles.” BMES 2018. Atlanta, GA – 10/2018. 
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3. Griffin MT and Ku DN. “Arterial Thrombosis Microfluidics: Control of the 
Third Dimension by Grayscale Lithography.” Micro and Nano Flows 2018. 
Atlanta, GA – 9/2018. 
4. Zhu Y, Griffin MT, Liu Z, Ku DN, Aidun CK. “Controlling the Conformational 
Changes of vWF in Shear Flow with Charged Nanoparticles.” Micro and Nano 
Flows 2018. Atlanta, GA – 9/2018. 
5. Ku DN, Griffin MT, Zhu Y, Aidun CK. “Challenges of thrombosis modelling.” 
ISTH Congress. Dublin, Ireland – 7/2018.  
6. Ku DN, Griffin MT, Zhu Y, Aidun CK. “Hemodynamics Controls Thrombosis to 
Cause Heart Attacks and Strokes.” World Congress of Biomechanics 2018. 
Dublin, Ireland – 7/2018. 
7. Griffin MT and Ku DN. “Grayscale Lithography to Create 3-D Channels: 
Applications to High Shear Thrombosis Assays.” SB3C. Tucson, AZ – 7 /2017. 
8. Ku DN, Griffin MT, Zhu Y, Liu Z, Aidun CK. “Nanoparticle Inhibition of Shear 
Induced Platelet Aggregation.” ISTH Congress. Berlin, Germany – 7/2017. 
 
 
5.1.1 Aim 1: Reduction of microfluidic thrombosis assay variability through design 
factors. 
This aim 1 led to the development of a grayscale lithography technique for 
creating ramped sections to change the z-dimension of microfluidic geometries. 
Although we apply this technique specifically to high shear thrombosis microfluidic 
technology, it certainly is not specific to this application and may benefit others 
aiming to accomplish a similar lithography technique. Therefore, we published this 
work in the journal Biomicrofluidics so that the technique might reach a broader 
group of researchers [48].  
Through our parametric screening design, we were able to show that the 3D 
grayscale laser lithography technique creates stenotic test sections of precise 
geometry and enhanced shear rate repeatability, as compared to current CNC 
micromachining techniques. Additionally, we showed that fibrillar collagens 
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provide superior repeatability in the MTA over collagen thin films, even though thin 
film approach provides a significantly more uniform surface. Although comparisons 
have been made between fibrillar and collagen thin films before for the strength of 
platelet responses to the type of collagen coating, this is a new finding showing that 
sparse fibers still produce a more repeatable platelet test. Additionally, we show in 
this study that the anticoagulation method (citrate vs. heparin) does not significantly 
impact the endpoint variability across experimental replicates. Finally, it was 
determined that clot formation consistently occurred in the first 0.3 mm of the 
stenotic channel with a constant pressure head, providing a basis by which to design 
optical detection methods in SIPA point-of-care diagnostic devices. 
5.1.2 Aim 2: Assess the ability of the MTA to quantify antiplatelet responsiveness. 
This aim 2 was focused on the continued development of in vitro diagnostics for 
thrombosis and antiplatelets. First, we were able to demonstrate that the MTA is capable 
of detecting antiplatelet effects in a group of healthy individuals taking low-dose aspirin 
therapy. This is significant because it determined a therapeutic cut-off value for the OT 
metric from baseline values that was able to be utilized in the study of cardiology patients. 
Further, we were able to show that the MTA does not correlate strongly to VerifyNow, 
which only uses biochemical agonists, and GTT, which only incorporates high shear and 
not biochemical agonists. It was also found that the MTA was less sensitive to antiplatelet 
medications than each of the other two devices, indicating that the combination of 
biochemical agonists (i.e. collagen) and high shear may lead to the development of a more 
stable clot more similar to the one that develops in the in vivo setting. This lower sensitivity 
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may lead to higher specificity of the MTA in determining if a patient truly is responsive to 
a given antiplatelet therapy. 
5.1.3 Aim 3: Development of a novel nanoparticle antithrombotic therapy. 
 This study effectively demonstrates the antithrombotic potential of CNP when 
administered in vitro and assessed in the MTA. We defined parameters for negatively 
charged, 50 nm polystyrene nanoparticles in order to achieve a reliable, strong 
antithrombotic response in vitro. The CNP decrease the rate of platelet adhesion and also 
decrease the total amount of platelet surface coverage within the stenotic zone of the MTA, 
indicating that clots form slower and are potentially weaker than clots under normal 
conditions. We also demonstrated that nanoparticle parameters of size and charge do not 
necessarily translate equally to other nanoparticle materials, as both gold and PLGA based 
nanoparticles of the same size and charge do not demonstrate the same effect. Therefore, 
conclusions about an antithrombotic response with one material cannot be made for another 
material even if all other factors are equal. 
 While efficacy results in vivo are modest and paired with concerns of respiratory 
complications after high-dose administration in mice, this study opens the door for further 
investigation into CNP modifications for increasing circulation residence time, and thus 
decreasing the effective dosing. Further, the in vivo experiments show no significant 
increase in bleeding due to CNP. As such, CNP may open the door to a new type of 
antithrombotic therapy that acts through biophysical means as opposed to traditional 
biochemical pathways of traditional agents. 
5.2  Future directions 
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5.2.1 Diagnostics for antiplatelet therapies 
Future directions of the MTA diagnostic are first to create a fully automated system 
that can detect occlusion time without the use of a microscope or mass balances. The 
quickest option to do so is to investigate modifications with the automated GTT unit. The 
GTT already incorporates high shear through a microfluidic-like channel in its cartridge. 
The material of the ceramic balls may have to be changed to something that is more 
thrombogenic. Also, anticoagulation with heparin is recommended for blood samples 
tested for high shear occlusion so that samples do not need to be tested immediately after 
the blood draw, making it easier on the technician or phlebotomist running the diagnostic. 
A comparative study of these modifications with the current state of the MTA will be useful 
to see if they provide the same OT endpoint. If not, then a custom automated system for 
the MTA with either a drop-counter or laser-diode optic at the stenosis could be developed. 
Following the creation of an automated device, the MTA should be validated in a 
large, multi-center study designed to test individuals who are at risk for MACE and taking 
an antiplatelet therapy of interest (i.e. DAPT). Those patients could then be followed-up 
over the course of a multi-year study to see if they experienced a major event. The 
sensitivity and specificity of the MTA could then be determined for predicting MACE. 
Similar studies have been performed for all of the other major PFTs and would certainly 
be valuable to validate the MTA for MACE prediction. 
5.2.2 CNP Antithrombotic Therapy 
Significantly more work can be performed to further the research of the CNP 
antithrombotic therapy. First, CNP should be tested in an in vivo murine stroke model to 
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determine its effect on thrombus formation. This can be accomplished at a much lower 
loading dose with PLGA-PVA CNP over PSC50 CNP, as the PLGA-PVA are designed to 
remain in the blood circulation for a much longer time period due to their hydrophilic 
nature. While this was not performed in this thesis, it should be performed to see if this 
antithrombotic effect found in vitro can be replicated in vivo. 
If the PLGA-PVA CNP were proven to be effective, further work would need to be 
accomplished in order to specifically define the blood circulation half-life of these particles 
and determining their “effective” half-life after venous injection. Particles will need to have 
an effective half-life over 24 hours so that particle dosing would be at most a daily 
occurrence. This can be initially characterized in the mouse carotid stroke model, where 
longer time points greater than tracking flow for 60 minutes post injury can be performed. 
An investigation into the mechanism of action by CNP can also be undertaken to 
better understand what CNP are doing, which may help in the smart design of CNP for 
antithrombotic effects. Based off of our hypothetical mechanism of CNP-vWF interactions 
preventing vWF-platelet interactions at high shear, one could perform single-molecular 
studies on vWF proteins under flow. By adhering a single vWF domain to a surface within 
a microfluidic chamber, vWF extension can be characterized under a range of flow rates. 
By adding CNP into the flow chamber with the vWF molecule, the effects of CNP on vWF 
extension could be monitored and quantified. Fluorescently tagging the CNP would also 
be useful, so that if changes in folding dynamics are not observed, direct CNP-vWF 
interactions that do not impact folding but rather impact vWF sterically can also be 
observed. If the mechanism is not through CNP-vWF interactions, then additional studies 
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investigating CNP-platelet interactions may need to be developed as the next logical target 
of CNP action.  
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APPENDIX A. GREYSCALE LITHOGRAPHY WITH DIRECT 
LASER WRITING 
  
High shear thrombosis assays are utilized in both clinical and research settings to 
analyze and assess platelet function and thrombus formation characteristics. However, 
these assays are susceptible to large amounts of variability due to factors such as individual 
blood biochemistry, anti-coagulation methods, experimental setup, and device channel 
geometry. It is worthwhile to reduce all sources of variability in order to acquire the most 
accurate metric that is desired in the assay. While all four areas require attention, this report 
details a method by which to reduce variability due to the geometry of the device. 
Previous microfluidic applications in the field of high shear thrombosis have largely 
utilized standard 2-dimensional (2D) lithography approaches in device fabrication. 
However, 2D lithography, by definition, is limited to geometric variations in the x- and y-
directions of the wafer substrate. The height (z-direction) is therefore conserved at typically 
100 µm or less in both the nominal and constricted or stenotic test sections of the flow 
channel. This leads to a drastic increase in total resistance along the flow path, making it 
difficult to achieve physiological shear rates (500-1000 s-1 in the nominal and > 5000 s-1 in 
the test sections) under constant pressure due to gravity driven flow. Therefore, these 
assays must make use of pumps to drive flow, which can lead to large undesirable increases 
in pressure within the flow channels as an occlusive thrombus forms. 
3-dimensional (3D) lithography approaches have the potential to alleviate the issues 
presented within standard methods of high shear platelet assays. The introduction of 
‘greyscale lithography’ provided a drastic change in microfabrication technology; 
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however, it remains an expensive option that is limited mainly to industry. A few simulated 
greyscale approaches have been devised, such as with the use of a liquid photomask with 
axial variations in dye concentration along the channel, thus altering the amount of UV 
exposure to the substrate. However, the control of dye concentration along the channel is 
not highly regulated and can thus lead to variations arising from channel to channel. CNC 
machining is an alternative for 3D geometries, but is not as desirable as lithography in 
terms of surface roughness and geometric repeatability. An automated lithography practice 
is therefore preferred in the development of 3D geometries in microfluidics. This report 
introduces a method for the creation of a microfluidic chip for physiologically relevant 
high shear thrombosis assays through the use of an automated ‘greyscale’ 3D lithography 
approach. 
A.1  Lithography Methods 
100 mm silicon wafers were coated with positive photoresist (Microposit SC1827) 
to a desired thickness of approximately 4.75 to 5.0 microns. The wafer was spun at 500 
rpm for 10 seconds, followed by a 5 second ramp to 1500 rpm for 40 seconds, but was later 
increased to 1750 rpm in order to decrease the thickness (noted when this change occurred). 
The coated wafer was then baked at 115°C for two minutes in order to crosslink the 
photoresist. After exposure with the laserwriter, the wafer was developed in MF-319 with 
agitation for a time specified in each condition. All measurements were acquired through 
the use of a contact profilometer (Dektak). All etch steps were performed with a BOSCH 
etch process in the Pettit cleanroom STS ICP; however, the number of cycles depends on 
the individual process being run and should be determined separately for each project. 
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Characterization of Intensity, Gain, and Bias 
In order to develop a defined slope gradient on a silicon wafer, a greyscale 
lithography approach was taken with the use of direct laser writing (Microtech Laserwriter 
LW405). Initially, it was important to investigate the effects of laser intensity, gain, and 
bias on the resulting photoresist height. Eleven different gain and bias pairings were 
selected, and eleven different ridges of varying laser intensities were exposed for each of 
those pairings. The wafer was developed for 50 seconds after exposure. 
Two comparisons can be made with this data in Figure A-1. The first is by holding 
the gain constant at 30.1 and varying the bias from 2.1 to 12.0 over the array of exposure 
intensities. Secondly, we can hold the bias constant at 8.0 and study the effects of varying 
the gain from 20.0 to 40.0 over the array of exposures. From these results, we can see that 
a constant gain slightly converges as the laser intensity increases, while the constant bias 
scenario diverges from a single thickness value as laser intensity increases. Bias controls 
the thickness in the low intensity regime, while gain controls thickness in high intensity. 
After an initial exposure, it appears that the thickness and intensity are nearly linearly 




Figure A-1. Constant gain analysis at 30.1 (left) and constant bias analysis at 8.0 
(right). 
Remaining gain and bias settings tested on the same wafer included gains of 54.6, 
49.9, and 33.2 with bias of 0.0, 4.7, and 8.2, respectively. The results in Figure A-2 confirm 
the control of thickness by bias at low intensities and gain at high intensities. 
 
Figure A-2. Varying gain and bias together from high difference (red) to lower 
difference (green). 
8-Bit Greyscale Range 
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The decision was also made to investigate 256 different levels of exposure over an 
8-bit greyscale range for 53.6 gain and 0.0 bias. Therefore, each channel corresponded to 
a 0.39% increase in UV-exposure over the 0 to 100% exposure range. Three repeats were 
performed under these conditions with photoresist thicknesses measured for each of the 
256 channels. In each repeat, a 2.0% exposure intensity led to the initiation of the linear 
relationship between thickness and intensity. The average of the three repeats showed that 
the photoresist was completely removed from the wafer at 52.0 ± 2.8% exposure, as seen 
in Figure A-3. 
 
Figure A-3. Representative 8-bit greyscale exposure curve. 
It is interesting that the three repeats showed this result, while the results from the 
previous investigation of varying gain, bias, and intensity found a more linear relationship 
across the entire spectra of laser intensities, regardless of gain or bias settings. However, 
the more complete analysis done in replicates across all 256 channels of greyscale shows 
an initial photoresist removal at low exposure settings that initiates the expected linear 
region until a specific value (in this case, around 50%). Afterward, all of the photoresist 
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has been removed from the wafer (with some noise in the profilometer measurement) at 
the end. 
Narrowed Greyscale Range on Bosch Etch 
An investigation on the full depth exposure was performed, where a baseline 2% 
laser intensity was utilized and the final laser intensity was varied from 5 to 50% over 11 
different channels. The channel with 10% intensity (channel 10) had a defect in the 
photoresist and was therefore excluded in measurements. Roughness was calculated as the 
difference between the maximum and minimum measurements taken in the fully exposed 
region. A Bosch etch process with 208 cycles were utilized for an estimated depth target 
of 125 microns. From the profilometer data in Table A-1, this target was overshot and less 
cycles should have been utilized. Channels 1 and 2 were the only channels to have 
roughness values of 0.0 and reach the full depth upon etching. Therefore, for resist 
thicknesses in the range of 4.75 microns, a laser intensity of 47% and beyond is acceptable 














1 50 146.1 0.0 23.4 
2 47 146.1 0.0 21.8 
3 45 146.1 27.1 22.2 
4 40 83.0 6.9 20.6 
5 35 54.7 5.9 15.9 
6 30 19.0 6.0 16.2 
7 25 2.9 0.0 0.2 
8 20 2.4 0.0 0.2 
9 15 1.9 0.0 0.2 
10 10 NA NA NA 




Figure A-4. Varying laser intensity effects on pre-etch (left) and post-etch (right) 
profiles. 
Gradient Region Length and Convergence Angle 
To further investigate the repeatability of the laser intensity at full exposure for 
fully clearing away photoresist in the test section of the channel, 4-channel devices were 
created on a wafer with photoresist thickness of 4.75 microns with the settings detailed in 
Table A-2. Final laser intensity was varied from 44 to 50%, while the length of the 
converging and diverging regions was varied for a few of the channels to assess its effect 
on reducing the final angle value. The assessment showed that intensities up to 49% still 
had variations in the depth greater than 1.0 micron, while all 50% intensity groups had 
SEM values below 0.6 microns. Therefore, a range of 2-50% laser intensity was selected 
as the nominal to full exposure values for this application. 
In addition, the target angle for this application was 15.0 degrees. A length of 667 
microns should have achieved this angle per Pythagorean theorem, but larger angles were 
observed. A length of 867 microns yielded an angle of 21.0 degrees. It was decided that 
final designs of the converging and diverging sections would be of length 1000 microns, 
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but no larger as to not create lengthy angled regions where step gradients from varying 
laser intensities would become more prominent.  
Table A-2. Determination of laser intensity at full exposure and length of gradient to 
achieve target angle. 
# 
Full Exposure 












1 50 867 201.1 0.2 21.0 0.3 
2 50 767 203.0 0.0 22.2 0.2 
3 50 667 200.4 0.2 26.3 0.2 
4 46 667 190.9 4.7 24.7 0.3 
5 47 667 193.0 4.3 24.5 0.6 
6 48 667 191.7 3.8 25.1 0.2 
7 49 667 192.5 4.3 25.1 0.3 
8 50 667 196.8 0.6 26.2 0.3 
9 50 667 200.8 0.2 25.9 0.2 
10 44 667 196.2 0.8 24.6 0.3 
11 45 667 198.6 0.3 25.8 0.4 
 
50% Intensity and 1000um Gradient Length 
A length of 1000 microns was investigated in the converging and diverging regions 
in order to reduce the angle value. While this goal was achieved through yielding values 
below 20.0 degrees, only the devices in the center of the wafer (5, 6, and 7) did not have 
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defects in them after the etch process. The defects were assumed to be due to the thickness 
at the edges of the wafer being greater than desired, thus the resist was not fully exposed 
and cleared in these regions. A slightly higher RPM was selected on the next wafer to test 
the same settings again. 



















5 50 1000 181.8 0.3 18.4 0.1 
6 50 1000 183.4 0.1 19.1 0.3 
7 50 1000 181.3 0.2 20.0 0.3 
 
After spinning photoresist on a wafer at 1750 rpm rather than 1500 rpm for 40 
seconds, the wafer was exposed and etched following the previously described methods 
and parameters. The results in Table A-4 show that repeatable measurements were 
obtained for devices using this method, particularly for devices in the center portion of the 
wafer (devices 5, 6, and 7). 
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1 50 1000 221.7 0.3 
2 50 1000 219.5 0.0 
3 50 1000 219.8 0.3 
4 50 1000 227.5 1.2 
5 50 1000 219.6 0.0 
6 50 1000 217.3 0.2 
7 50 1000 217.8 0.0 
8 50 1000 224.6 1.3 
9 50 1000 223.2 0.3 
10 50 1000 219.9 0.1 
11 50 1000 222.2 0.5 
 
Final Design with 3 Functional Devices 
Utilizing the parameters detailed in the steps above, 11 devices were created on a 
1mm thick silicon wafer. Photoresist was spun on the wafer at 1750 RPM. The laserwriter 
was utilized at 0 bias, 53.5 gain, 30% filter, lens 2, d-step 3, and intensity range from 2-
50%. STS ICP BOSCH process was used at 200 cycles to a target stenotic depth of 180 
microns. AZ6240 was then spray coated on the wafer to a thickness of approximately 10 
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microns, followed by a mask aligning process to align the overall device geometry on the 
wafer. STS ICP BOSCH process was used at 800 cycles to a target nominal depth of 250 
microns (or stenotic height to 70 microns). From this process, three functional devices were 
created in the center of the wafer, with the edge devices having some sort of noticeable 
defect in the channels after the etch process. The profiles of the three functional devices 
are summarized in Table A-5. 
Table A-5. Final device design measurements. 
Device Stenotic Height (um) Stenotic Depth (um) Angle (deg) 
5 76.9 ± 0.3 180.5 ± 0.1 19.4 ± 0.3 
6 73.7 ± 0.1 182.3 ± 0.1 20.0 ± 0.3 
7 75.8 ± 0.4 180.4 ± 0.4 19.2 ± 0.7 
 
Future work to minimize channel variability and creation of functional devices on 
the edges of the wafer could look to utilize spray coating at all coating steps rather than 
spin coating. Spray coating may allow for a more uniform thickness over the entire wafer, 
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